Applied DNA Sciences (APDN) 10-K 20 Dec 13 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 30, 2013	Dec. 16, 2013	Mar. 31, 2013
Document and Entity Information [Abstract]	'	'	'
Entity Registrant Name	'APPLIED DNA SCIENCES INC	'	'
Entity Central Index Key	'0000744452	'	'
Trading Symbol	'apdn	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Current Fiscal Year End Date	'--09-30	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Well-Known Seasoned Issuer	'No	'	'
Entity Common Stock, Shares Outstanding	'	805,350,028	'
Entity Public Float	'	'	$113
Document Type	'10-K	'	'
Document Period End Date	30-Sep-13	'	'
Amendment Flag	'false	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2013	Sep. 30, 2012
Current assets:	'	'
Cash and cash equivalents	$6,360,301	$724,782
Accounts receivable, net of allowance of $62,415 and $0 at September 30, 2013 and 2012, respectively	672,638	296,994
Prepaid expenses	174,096	80,037
Total current assets	7,207,035	1,101,813
Property, plant and equipment-net of accumulated depreciation of $409,629 and $251,958, respectively	695,995	210,845
Other assets:	'	'
Deposits	51,260	36,276
Intangible assets:	'	'
Intellectual property, net of accumulated amortization and impairment of $163,403 and $0, respectively	420,676	'
Total Assets	8,374,966	1,348,934
Current liabilities:	'	'
Accounts payable and accrued liabilities	966,977	592,009
Deferred revenue	148,503	'
Total current liabilities	1,115,480	592,009
Warrant liability	2,643,449	'
Total liabilities	3,758,929	592,009
Commitments and contingencies	'	'
Stockholders' Equity	'	'
Preferred stock, value	'	'
Common stock, par value $0.001 per share; 1,350,000,000 shares authorized; 786,526,955 and 646,182,550 shares issued and outstanding as of September 30, 2013 and 2012, respectively	786,527	646,183
Additional paid in capital	190,523,121	169,117,881
Accumulated deficit	-186,693,611	-169,007,139
Total stockholders' equity	4,616,037	756,925
Total Liabilities and Stockholders' Equity	8,374,966	1,348,934
Series A Preferred stock	'	'
Stockholders' Equity	'	'
Preferred stock, value	'	'
Series B Preferred stock	'	'
Stockholders' Equity	'	'
Preferred stock, value	'	'

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) (USD $)	Sep. 30, 2013	Sep. 30, 2012
Allowance on accounts receivable	$62,415	$0
Accumulated depreciation on property, plant and equipment	409,629	251,958
Accumulated amortization and write off on intellectual property	$163,403	$0
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized (in shares)	1,350,000,000	1,350,000,000
Common stock, shares issued (in shares)	786,526,955	646,182,550
Common stock, shares outstanding (in shares)	786,526,955	646,182,550
Series A Preferred stock	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Series B Preferred stock	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Income Statement [Abstract]	'	'
Revenues	$2,036,222	$1,854,694
Operating expenses:	'	'
Selling, general and administrative	11,198,505	7,615,734
Research and development	692,480	432,669
Depreciation and amortization	321,074	313,940
Total operating expenses	12,212,059	8,362,343
LOSS FROM OPERATIONS	-10,175,837	-6,507,649
Other income (expense):	'	'
Interest income (expense), net	1,272	-643,063
Other (expense) income, net	-3,761	'
Loss on change in fair value of warrant liability	-7,508,146	'
Loss before provision for income taxes	-17,686,472	-7,150,712
Income taxes (benefit)	'	'
NET LOSS	($17,686,472)	($7,150,712)
Net loss per share-basic and diluted (in dollars per share)	($0.03)	($0.01)
Weighted average shares outstanding-	'	'
basic and diluted (in shares)	703,852,716	576,091,498

CONSOLIDATED_STATEMENTS_OF_STO

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (USD $)	Preferred Stock	Common Stock	Additional Paid in Capital	Accumulated Deficit	Total
Balance at Oct. 01, 2011	'	$473,326	$160,387,716	($161,856,427)	($995,385)
Balance (in shares) at Oct. 01, 2011	'	473,325,859	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'
Common stock issued in settlement of convertible debentures and interest	'	122,532	4,667,408	'	4,789,940
Common stock issued in settlement of convertible debentures and interest (in shares)	'	122,531,901	'	'	'
Sale of common stock	'	44,964	2,056,036	'	2,101,000
Sale of common stock (in shares)	'	44,963,516	'	'	'
Exercise of warrants and options cashlessly	'	5,361	-5,361	'	'
Exercise of warrants and options cashlessly (in shares)	'	5,361,274	'	'	'
Fair value of warrants issued for services	'	'	58,238	'	58,238
Equity based compensation	'	'	1,953,844	'	1,953,844
Net loss	'	'	'	-7,150,712	-7,150,712
Balance at Sep. 30, 2012	'	646,183	169,117,881	-169,007,139	756,925
Balance (in shares) at Sep. 30, 2012	'	646,182,550	'	'	646,182,550
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'
Sale of Series A preferred stock	6	'	5,499,994	'	5,500,000
Sale of Series A preferred stock (in shares)	5,500	'	'	'	'
Sale of Series B preferred stock	6	'	5,234,994	'	5,235,000
Sale of Series B preferred stock (in shares)	5,500	'	'	'	'
Sale of common stock	'	21,448	1,416,698	'	1,438,146
Sale of common stock (in shares)	'	21,447,875	'	'	'
Common stock issued in conversion of Series A preferred stock	-6	25,463	-25,457	'	'
Common stock issued in conversion of Series A preferred stock (in shares)	-5,500	25,462,963	'	'	'
Common stock issued in conversion of Series B preferred stock	-6	42,308	-42,302	'	'
Common stock issued in conversion of Series B preferred stock (in shares)	-5,500	42,307,692	'	'	'
Exercise of warrants and options	'	1,525	149,975	'	151,500
Exercise of warrants and options (in shares)	'	1,525,000	'	'	'
Purchase and cancellation of issued warrants	'	'	-60,000	'	-60,000
Fair value of warrants issued for services	'	'	28,256	'	28,256
Reclassification of warrants upon exercise	'	'	7,326,553	'	7,326,553
Exercise of warrants cashlessly	'	44,961	-44,961	'	'
Exercise of warrants cashlessly (in shares)	'	44,961,392	'	'	'
Equity based compensation	'	'	1,926,129	'	1,926,129
Exercise of options cashlessly	'	4,639	-4,639	'	'
Exercise of options cashlessly (in shares)	'	4,639,483	'	'	'
Net loss	'	'	'	-17,686,472	-17,686,472
Balance at Sep. 30, 2013	'	$786,527	$190,523,121	($186,693,611)	$4,616,037
Balance (in shares) at Sep. 30, 2013	'	786,526,955	'	'	786,526,955

CONSOLIDATED_STATEMENT_OF_CASH

CONSOLIDATED STATEMENT OF CASH FLOWS (USD $)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities:	'	'
Net loss	($17,686,472)	($7,150,712)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	206,344	313,940
Impairment of intellectual property	114,730	'
Fair value of vested options issued to officers, directors and employees	1,517,524	1,953,844
Change in fair value of warrant liability	7,508,146	'
Amortization of capitalized financing costs	'	85,975
Amortization of debt discount attributable to convertible debentures	'	541,120
Fair value of vested warrants issued for service	28,256	58,238
Common stock issued in settlement of interest	'	102,844
Fair value change from employee option modifications	408,605	'
Bad debt expense	77,415	'
Change in operating assets and liabilities:	'	'
Accounts receivable	-453,059	-88,407
Prepaid expenses and deposits	-109,042	-16,565
Accounts payable and accrued liabilities	517,200	239,044
Net cash used in operating activities	-7,870,353	-3,960,679
Cash flows used in investing activities:	'	'
Purchase of assets under RedWeb asset purchase agreement	-584,080	'
Purchase of property and equipment	-636,548	-162,833
Net cash used in investing activities	-1,220,628	-162,833
Cash flows from financing activities:	'	'
Net proceeds from sale of Series A and Series B Preferred Stock	10,735,000	'
Net proceeds from sale of common stock and warrants	3,900,000	2,101,000
Purchase and cancellation of previously issued warrants	-60,000	'
Proceeds from exercise of options and warrants	151,500	'
Net cash provided by financing activities	14,726,500	2,101,000
Net increase (decrease) in cash and cash equivalents	5,635,519	-2,022,512
Cash and cash equivalents at beginning of year	724,782	2,747,294
Cash and cash equivalents at end of year	6,360,301	724,782
Supplemental Disclosures of Cash Flow Information:	'	'
Cash paid during period for interest	'	'
Cash paid during period for income taxes	'	'
Non-cash investing and financing transactions:	'	'
Fair value of warrants issued for financing costs	'	'
Property, plant and equipment acquired, and included in accounts payable	6,273	'
Common stock issued upon conversion of Series A and Series B preferred stock	67,759	'
Common stock issued for cashless exercise of options and warrants	49,600	'
Common stock issued in exchange for previously incurred debt and related accrued interest	'	$4,687,096

LIQUIDITY_AND_MANAGEMENTS_PLAN

LIQUIDITY AND MANAGEMENT'S PLAN	12 Months Ended
	Sep. 30, 2013
Liquidity And Management Plan [Abstract]	'
LIQUIDITY AND MANAGEMENT'S PLAN	'
	NOTE A – LIQUIDITY AND MANAGEMENT’S PLAN
	The Company incurred a net loss of $17,686,472 and generated negative operating cash flow of $7,870,353 for the fiscal year ended September 30, 2013.  However, the Company has attained positive working capital of $6,091,555 as of September 30, 2013.
	As discussed in Note H, during the year ended September 30, 2013, the Company entered into two securities purchase agreements on November 28, 2012 and July 19, 2013, respectively, with an institutional investor (“Crede”) to sell an aggregate of $15.0 million ($7.5 million per agreement) of our securities.  The total net proceeds received under these two transactions were $14.6 million ($15 million gross proceeds, less investment fees of $365,000).
	Management believes that the Company’s positive cash balance and working capital as of September 30, 2013 along with its current customer base, projected cash flow and the minimum projected revenues for the next fiscal year will allow the Company to continue to improve its working capital and to have sufficient capital resources to meet projected cash flow requirements for the next twelve months from the filing date of this report. However, if the Company does not meet its minimum revenue projections for the next fiscal year, the Company may be required to seek additional capital.  The Company has no commitments for any future funding, and may not be able to obtain additional financing or grants on terms acceptable to it, if at all, in the future. If the Company is unable to obtain additional capital this could restrict its ability to grow. Financing transactions may include the issuance of equity or debt securities, obtaining credit facilities, or other financing mechanisms.  Even if the Company is able to raise the funds required, it is possible that it could incur unexpected costs and expenses, fail to collect significant amounts owed to the Company, or experience unexpected cash requirements that would force the Company to seek alternative financing.  In accordance with its financing agreements with Crede (described below), the Company has agreed not to issue additional Common Stock or securities convertible into Common Stock at a price below the per share price issued to Crede under the Second Purchase Agreement, $0.187, or the market price of the Common Stock on the day before the registration statement was declared effective ($0.167), for a period of 180 days from the effective date of the registration statement, which was declared effective on July 31, 2013.  Further, if the Company issues additional equity or debt securities, stockholders may experience additional dilution or the new equity securities may have rights, preferences or privileges senior to those of existing holders of the Company’s common stock.

SUMMARY_OF_ACCOUNTING_POLICIES

SUMMARY OF ACCOUNTING POLICIES	12 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
SUMMARY OF ACCOUNTING POLICIES	'
	NOTE B — SUMMARY OF ACCOUNTING POLICIES
	Business and Basis of Presentation
	On September 16, 2002, Applied DNA Sciences, Inc. (the “Company”) was incorporated under the laws of the State of Nevada.  Effective December 17, 2008, the Company reincorporated from the State of Nevada to the State of Delaware.  The Company is principally devoted to developing DNA embedded biotechnology security solutions in the United States and Europe.  To date, the Company has generated limited sales revenues from services and products; it has incurred expenses and has sustained losses.  Consequently, its operations are subject to all risks inherent in the establishment of an early stage company.  For the period from inception through September 30, 2013, the Company has accumulated losses of $186,693,611.
	The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Applied DNA Operations Management, Inc., APDN (B.V.I.) Inc. and Applied DNA Sciences Europe Limited, which currently have no operations.  Significant inter-company transactions have been eliminated in consolidation.
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect certain reported amounts and disclosures.  Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources.  The most complex and subjective estimates include; recoverability of long-lived assets, including the value assigned to intangible assets and property and equipment, fair value calculations for warrants, contingencies and allowances for doubtful accounts.  Management reviews its estimates on a regular basis and the effects of any material revisions are reflected in the consolidated financial statements in the period they are deemed necessary.  Accordingly, actual results could differ from those estimates.
	Reclassifications
	Certain reclassifications have been made in prior year’s financial statements to conform with the current year’s financial statements’ presentation.
	Revenue Recognition
	The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) 605, Revenue Recognition (“ASC 605”).  ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and/or service has been performed; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured.  Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered or services provided and the collectability of those amounts.  Provisions for allowances and other adjustments are provided for in the same period the related sales are recorded.  The Company defers any revenue for which the product has not been delivered, service has not been provided, or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered, the service has been provided, or no refund will be required.  At September 30, 2013 and 2012, the Company recorded deferred revenue of $148,503 and $0, respectively.
	Revenue arrangements with multiple components are divided into separate units of accounting if certain criteria are met, including whether the delivered component has stand-alone value to the customer.  Consideration received is allocated among the separate units of accounting based on their respective selling prices.  The selling price for each unit is based on vendor-specific objective evidence, or VSOE, if available, third party evidence if VSOE is not available, or estimated selling price if neither VSOE nor third party is available.  The applicable revenue recognition criteria are then applied to each of the units.
	Revenue for a Government contract award, which supports our development efforts on specific projects is recognized as milestones are achieved as per the contract.  The Company recognized revenue of $100,000 from this contract during the year ended September 30, 2013.
	Cash Equivalents
	For the purpose of the accompanying consolidated financial statements, all highly liquid investments with a maturity of three months or less are considered to be cash equivalents.
	Accounts Receivable
	The Company provides an allowance for doubtful accounts equal to the estimated uncollectible amounts.  The Company’s estimate is based on historical collection experience and a review of the current status of trade accounts receivable.  It is reasonably possible that the Company’s estimate of the allowance for doubtful accounts will change.  At September 30, 2013 and 2012, the Company has an allowance for doubtful accounts of $62,415 and $0, respectively.  The Company writes-off receivables that are deemed uncollectible.  The Company wrote-off $15,000 and $0 of accounts receivable that was not previously reserved for during the year ended September 30, 2013 and 2012, respectively.
	Income Taxes
	The Company accounts for income taxes in accordance with ASC 740, Income Taxes (“ASC 740-10”) which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statement or tax returns.  Under this method, deferred tax liabilities and assets are determined based on the difference between financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Temporary differences between taxable income reported for financial reporting purposes and income tax purposes include, but not limited to, accounting for intangibles, warrants, equity based compensation and depreciation and amortization.
	The Company evaluates the recoverability of deferred tax assets and establishes a valuation allowance when it is more likely than not that some portion or all of the deferred tax asset will not be realized.  During the years ended September 30, 2013 and 2012, the Company incurred losses from operations. Based upon these results and the trends in the Company’s performance projected for fiscal year 2014, it is more likely than not that the Company will not realize any benefit from the deferred tax assets recorded by the Company in previous periods.  Management makes judgments as to the interpretation of tax laws that might be challenged upon an audit and cause changes to previously estimates of tax liability.  In management’s opinion, adequate provisions for income taxes have been made for all years.  If actual taxable income by tax jurisdiction varies from estimates, additional allowances or reversals of reserves may be necessary.  The Company has identified its federal tax return and its state tax return in New York as “major” tax jurisdictions.  Based on the Company’s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company consolidated financial statements.
	The Company’s evaluation was performed for tax years 2009 through 2012.  The Company believes that its income tax positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position.  It is the Company’s policy to accrue interest and penalties on unrecognized tax benefits as components of income tax provision.  The Company did not have any accrued interest or penalties as of September 30, 2013 and 2012.
	Property Plant and Equipment
	Property Plant and equipment are stated at cost and depreciated using the straight line method over their estimated useful lives.  The estimated useful for computer equipment, lab equipment and furniture is 3 to 5 years and leasehold improvements are amortized over the shorter of their useful life or the lease terms.  Property plant and equipment consist of:
		September 30,
		2013		2012
	Computer equipment	$	43,555	$	33,464
	Lab equipment		657,735		296,904
	Furniture		164,997		132,435
	Leasehold improvements		239,337		-
	Total		1,105,624		462,803
	Accumulated depreciation		409,629		251,958
	Property and equipment, net	$	695,995	$	210,845
	Depreciation expense for the years ended September 30, 2013 and 2012 were $157,671 and $41,096, respectively.
	Impairment of Long-Lived Assets
	The Company accounts for its long-lived assets in accordance with ASC 360, Property, Plant and Equipment (“ASC 360”).  ASC 360 requires that long-lived assets and certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  The Company evaluates its long lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a forecasted inability to achieve break-even operating results over an extended period.  The Company evaluates the recoverability of long-lived assets based upon forecasted undiscounted cash flows.  Should impairment in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset.  ASC 360 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less costs to sell. For the years ended September 30, 2013 and 2012, the Company recognized impairment charges of $114,730 and $0, respectively related to certain intellectual property.
	Segment Information
	The Company follows the provisions of ASC 280, Segment Reporting (“ASC 280-10”).  ASC 280 establishes standards for reporting information regarding operating segments in annual financial statements and requires selected information for those segments to be presented in interim financial reports issued to stockholders.  ASC 280 also establishes standards for related disclosures about products and services and geographic areas.  Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision- making group, in making decisions how to allocate resources and assess performance.  The information disclosed herein, materially represents all of the financial information related to the Company’s single principal operating segment.
	Net Loss per Share
	The Company presents loss per share utilizing a dual presentation of basic and diluted loss per share.  Basic loss per share includes no dilution and has been calculated based upon the weighted average number of common shares outstanding during the period.  Dilutive common stock equivalents consist of shares issuable upon the exercise of the Company’s stock options and warrants.
	For the years ended September 30, 2013 and 2012, common stock equivalent shares are excluded from the computation of the diluted loss per share as their effect would be anti-dilutive.
	Fully diluted shares outstanding were 839,583,895 and 692,328,470 for the years ended September 30, 2013 and 2012, respectively.
	Stock Based Compensation
	The Company accounts for stock-based compensation in accordance with ASC 718, Compensation (“ASC 718”).  ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statement of operations based on their fair values.  Under the provisions of ASC 718, stock-based compensation costs is measured at the grant date, based on the fair value of the award, and is recognized as expense over the employee’s requisite service period (generally the vesting period of the equity grant).  The fair value of the Company’s common stock options are estimated using the Black Scholes option-pricing model with the following assumptions:  expected volatility, dividend rate, risk free interest rate and the expected life.   The Company expenses stock-based compensation by using the straight-line method. In accordance with ASC 718, excess tax benefits realized from the exercise of stock-based awards are classified in cash flows from financing activities. The future realization of the reserved deferred tax assets related to these tax benefits associated with the exercise of stock options will result in a credit to additional paid in capital if the related tax deduction reduces taxes payable. The Company has elected the “with and without approach” regarding ordering of windfall tax benefits to determine whether the windfall tax benefit did reduce taxes payable in the current year. Under this approach, the windfall tax benefit would be recognized in additional paid-in-capital only if an incremental tax benefit is realized after considering all other benefits presently available.  Stock-based compensation expense recognized under ASC 718 for the years ended September 30, 2013 and 2012 was $1,926,129 and $1,953,844, respectively.
	Concentrations
	Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables.  The Company places its cash and temporary cash investments with high credit quality institutions.  At times, such investments may be in excess of the FDIC insurance limit.
	No customers represented greater than 10% of the Company’s total revenues for the year ended September 30, 2013. The Company’s revenues earned from sale of products and services for the year ended September 30, 2012 included an aggregate of 54% from two customers of the Company’s total revenues.  Three and two customers accounted 43% and 54% of the Company’s total accounts receivable at September 30, 2013 and 2012, respectively.
	Research and Development
	The Company accounts for research and development costs in accordance with the ASC 730, Research and Development (“ASC 730”).  Under ASC 730, all research and development costs must be charged to expense as incurred.  Accordingly, internal research and development costs are expensed as incurred.  Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved.  Company-sponsored research and development costs related to both present and future products are expensed in the period incurred.  The Company incurred research and development expenses of $692,480 and $432,669 for the years ended September 30, 2013 and 2012, respectively.
	Advertising
	The Company follows the policy of charging the costs of advertising to expense as incurred.  The Company charged to operations $196,762 and $97,877 as advertising costs for the years ended September 30, 2013 and 2012, respectively.
	Intangible Assets
	The Company amortizes its intangible assets using the straight-line method over their estimated period of benefit.  The estimated useful life for patents is five years while other intellectual property uses a seven year useful life.  The Company periodically evaluates the recoverability of intangible assets and takes into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists.  All of the Company’s intangible assets are subject to amortization.
	Fair Value of Financial Instruments
	The Company’s financial instruments are primarily composed of cash, accounts receivable, accounts payable and accrued liabilities, and warrants. The fair value of cash, accounts receivable, accounts payable and accrued liabilities, as reflected in the consolidated balance sheet, approximate its fair value due to the short-term maturity of these instruments.
	The valuation techniques utilized are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect internal market assumptions. These two types of inputs create the following fair value hierarchy:
	Level 1 – Quoted prices in active markets for identical assets or liabilities.
	Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related asset or liabilities.
	Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of assets or liabilities.
	The Company utilizes observable market inputs (quoted market prices) when measuring fair value whenever possible.
	For fair value measurements categorized within Level 3 of the fair value hierarchy, the Company’s accounting and finance department, who report to the Chief Financial Officer, determine its valuation policies and procedures. The development and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s accounting and finance department and are approved by the Chief Financial Officer.
	As of September 30, 2013, there were no transfers in or out of Level 3 from other levels.
	The fair value of each warrant is estimated using the Binomial Lattice option valuation model. Significant observable and unobservable inputs include stock price, exercise price, annual risk free rate, term, and expected volatility, and are classified within Level 3 of the valuation hierarchy. An increase or decrease in volatility, in isolation, can significantly increase or decrease the fair value of the warrant. See Note L.
	Recently Adopted Accounting Principles
	There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s consolidated financial position, results of operations or cash flows
Subsequent Events
The Company has evaluated events that occurred subsequent to the balance sheet date and through the date the financial statements were available to be issued. Other than those events disclosed in the notes to these consolidated financial statements, management concluded that no additional subsequent events required disclosure in these consolidated financial statements.

INTANGIBLE_ASSETS

INTANGIBLE ASSETS	12 Months Ended
	Sep. 30, 2013
Intangible Assets Disclosure [Abstract]	'
INTANGIBLE ASSETS	'
	NOTE C - INTANGIBLE ASSETS
	On May 10, 2013, the Company entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with RedWeb Technologies Limited (“RedWeb”), a corporation incorporated and registered under the laws of England & Wales, to purchase certain assets of RedWeb (“Purchased Assets”) relating to its forensic tagging security system for a purchase price of £400,000 ($624,080). The Company completed the acquisition of the Purchased Assets on the same day. The Purchased Assets include RedWeb’s Sentry 500 Intruder Spray System, RedWeb’s Advanced Molecular Taggent Technology and all products relating thereto, certain intellectual property and supplies relating to the foregoing. £40,000 ($62,408) of the purchase price shall be held in escrow for up to one year to be applied against the indemnification obligations of RedWeb pursuant to the Asset Purchase Agreement. This transaction was accounted for as an asset acquisition in accordance with ASC 805.  The Company assigned $584,080 of the purchase price to intellectual property and the remaining $40,000 was for supplies, which were expensed during the year ended September 30, 2013.
	The Company recorded impairment expense of $114,730 during the year ended September 30, 2013 related to certain intellectual property that was part of the purchased assets from RedWeb.  The impairment related to two pending patents that were no longer valid as of September 30, 2013.
	The identifiable intangible assets acquired and their carrying values at September 30, 2013 and 2012 are as follows:
		2013			2012
	Trade secrets and developed technologies (Weighted average life of 7 years)	$	-		$	3,775,889
	Patents (Weighted average life of 5 years)		-			34,257
	Intellectual property (Weighted average life of 5 years)		584,080			-
	Total identifiable intangible assets-Gross carrying value:		584,080			3,810,146
	Less:
	Accumulated amortization		(48,674	)		(3,810,146	)
	Impairment charges		(114,730	)		-
	Intangible assets, net	$	420,676		$	-
	Total amortization expense charged to operations for the years ended September 30, 2013 and 2012 were $163,404 (includes $114,730 of impairment expense) and $272,844, respectively.
	The following table presents the estimated amortization expense of the intangible assets for each of the five succeeding years as of September 30, 2013:
		Amount
	2014	$	90,145
	2015		90,145
	2016		90,145
	2017		90,145
	2018		60,096
	Total	$	420,676

ACCOUNTS_PAYABLE_AND_ACCRUED_L

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	12 Months Ended
	Sep. 30, 2013
Payables and Accruals [Abstract]	'
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	'
	NOTE D– ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
	Accounts payable and accrued liabilities at September 30, 2013 and 2012 are as follows:
		2013		2012
	Accounts payable	$	641,302	$	473,060
	Accrued consulting fees		102,500		102,500
	Accrued salaries payable		220,175		16,449
	Other accrued expenses		3,000		-
	Total	$	966,977	$	592,009

PRIVATE_PLACEMENT_OF_CONVERTIB

PRIVATE PLACEMENT OF CONVERTIBLE NOTES	12 Months Ended
	Sep. 30, 2013
Long-Term Debt, Unclassified [Abstract]	'
PRIVATE PLACEMENT OF CONVERTIBLE NOTES	'
	NOTE E – PRIVATE PLACEMENT OF CONVERTIBLE NOTES
	During the years ended September 30, 2011 and 2010 the Company issued multiple senior secured convertible promissory notes, all of which had been converted as of September 30, 2012.  The activity that occurred during the year ended September 30, 2012 is summarized below.
	10% Secured Convertible Promissory Note dated June 4, 2010
	On June 4, 2010, the Company issued a $675,000 related party convertible promissory note due January 31, 2012 with interest at 10% per annum due upon maturity.  In January 2012, the Company issued an aggregate of 6,750,248 shares of Common Stock in settlement of the convertible notes and related accrued interest.
	10% Senior Secured Convertible Promissory Notes dated July 15, 2010
	On July 15, 2010, the Company issued an aggregate of $2,000,000 senior secured convertible promissory notes due July 15, 2011 with interest at 10% per annum due upon maturity to “accredited investors,” as defined in regulations promulgated under the Securities Act of 1933, as amended (“Securities Act”).
	On January 7, 2011, upon the completion of a Subsequent Financing, the above described conversion rate changed from $0.04405 to $0.037104 with an extended due date from July 15, 2011 to January 7, 2012 on $1,550,000 of the $2,000,000 issued senior convertible promissory notes.  All other terms remained the same.  Although the conversion rate of the remaining $450,000 senior secured convertible promissory notes remained the same, the due date was extended also to January 7, 2012.  In conjunction with the conversion rate and term modifications of the $1,550,000 senior secured convertible promissory notes, the Company wrote off the remaining unamortized debt discount of $331,332 to operations.
	Amortization of $26,091 was recorded for the year ended September 30, 2012.
	In January 2012, the Company issued an aggregate of 11,729,821 shares of Common Stock in settlement of the $450,000 convertible notes and related accrued interest.  As described further below, the Company issued 1,497,826 and 44,778,815 shares on October 26, 2011 and January 7, 2012, respectively in settlement of the remaining $1,550,000 convertible notes and related accrued interest.
	10% Senior Secured Convertible Promissory Notes dated November 19, 2010
	On November 19, 2010, the Company issued an aggregate of $350,000 in principal amount of senior secured convertible notes bearing interest at a rate of 10% per annum to “accredited investors,” as defined in regulations promulgated under the Securities Act.
	The Company recorded the intrinsic value of the embedded beneficial conversion feature ($76,494) to debt discount which will be amortized to interest expense over the term of the notes. Amortization of $10,479 was recorded for the year ended September 30, 2012.
	In November 2011, the Company issued an aggregate of 11,693,102 shares of Common Stock in settlement of the convertible notes and related accrued interest.
	10% Senior Secured Convertible Promissory Note dated November 30, 2010
	On November 30, 2010, the Company issued a $750,000 principal amount senior secured convertible note bearing interest at a rate of 10% per annum to an “accredited investor,” as defined in regulations promulgated under the Securities Act.
	The Company recorded the intrinsic value of the embedded beneficial conversion feature ($270,078) to debt discount which will be amortized to interest expense over the term of the note. Amortization of $45,136 was recorded for the year ended September 30, 2012.
	On November 30, 2011, the Company issued an aggregate of 26,716,321 shares of Common Stock in settlement of the convertible note and related accrued interest.
	10% Senior Secured Convertible Promissory Note dated January 7, 2011.
	On January 7, 2011, the Company issued a $750,000 principal amount senior secured convertible note bearing interest at a rate of 10% per annum to an “accredited investor,” as defined in regulations promulgated under the Securities Act.
	Amortization of $65,159 was recorded for the year ended September 30, 2012.
	In January 2012, the Company issued an aggregate of 14,921,324 shares of Common Stock in settlement of the convertible note and related accrued interest.
	10% Senior Secured Convertible Promissory Notes issued on July 15, 2010, modified on January 7, 2011
	On January 7, 2011, the Company modified previously issued senior secured promissory notes initially dated July 15, 2010 totaling $1,550,000 in principal amount bearing interest at a rate of 10% per annum to “accredited investors,” as defined in regulations promulgated under the Securities Act
	The Company recorded the intrinsic value of the embedded beneficial conversion feature ($1,499,536) to debt discount which will be amortized to interest expense over the term of the notes. Amortization of $392,923 was recorded for the year ended September 30, 2012.
	On October 26, 2011, the Company issued 1,497,826 shares of Common Stock in settlement of $50,000 of convertible notes and related accrued interest.
	In January 2012, the Company issued an aggregate of 44,778,815 shares of Common Stock in settlement of the remaining $1,447,000 convertible notes and related accrued interest.
	4% Senior Secured Convertible Promissory Note issued on July 11, 2011
	On July 11, 2011, the Company issued a $250,000 related party convertible promissory note due July 11, 2012 with interest at 4% per annum due upon maturity.
	On July 11, 2012, the Company issued 4,444,444 shares of Common Stock in settlement of $250,000 of convertible notes and related accrued interest.

WARRANT_LIABILITY

WARRANT LIABILITY	12 Months Ended
	Sep. 30, 2013
Warrant Liability [Abstract]	'
WARRANT LIABILITY	'
	NOTE F – WARRANT LIABILITY
	As more fully described in Note H below, on November 28, 2012 the Company entered into a securities purchase agreement (“Initial Purchase Agreement”) with Crede CG II, Ltd and on July 19, 2013, the Company entered into an additional securities purchase agreement (“Second Purchase Agreement”) with Crede CG III, Ltd. (collectively referred to as “Crede” and “Purchase Agreements”).
	In connection with the Purchase Agreements, the Company issued Series A, B and C Warrants allowing Crede to purchase the shares of Common Stock detailed in the table below:
	Securities Issued	Initial Purchase Agreement				Second Purchase Agreement
		Shares issued		Price per share		Shares issued		Price per share
	Series A Warrants		10,752,688	$	0.2232		10,695,187	$	0.2431
	Series B Warrants		29,569,862	$	0.2232		29,411,764	$	0.2431
	Series C Warrants		26,881,720	$	0.2232		26,737,967	$	0.2431
	The Company determined that the Series A and B Warrants described above should be classified as a liability due to transactions which may cause an adjustment to the conversion rate (reset provisions) contained in the warrant agreements and re-measured at each reporting date at their fair value with the changes reported in earnings (loss). The Series C Warrants associated with the Initial Purchase Agreement were repurchased by the Company for $50,000 on January 22, 2013 and the Series C Warrants from the Second Purchase Agreement were repurchased on August 14, 2013 for $10,000.  Liability classification of the Series A and B Warrants will end upon expiration of reset provisions, at which time the Warrants will be reclassified to equity based on their then fair value.
	Initial Purchase Agreement:
	The Company determined the allocated fair value of the Warrants to be $1,181,324 on November 28, 2012, the issuance date using the Binomial Lattice model with the following assumptions: fair value of the Company’s Common Stock $0.20 per share; dividend yield 0%; expected terms 5 years; risk free interest rate: 0.64%; expected volatility of: 146.32%; and the expected price at which holders are likely to exercise their Warrants of $0.2232 per share.
	On April 25, 2013, Crede effected the cashless exercise of the Series A and Series B Warrants.  At April 25, 2013 (date of exercise), the Company determined the fair value of the Warrants to be $7,326,553 using the Binomial Lattice model with the following assumptions: fair value of the Company’s Common Stock $0.221 per share; dividend yield 0%; expected term: 4.54 years; risk free interest rate: 0.71%; expected volatility of: 125.97%; and an exercise price of $0.2232 per share. Upon exercise, the fair value of the Series A and Series B Warrants were reclassified to equity.
	Second Purchase Agreement:
	The Company determined the allocated fair value of the Warrants to be $1,280,532 on July 19, 2013, the issuance date using the Binomial Lattice model with the following assumptions: fair value of the Company’s Common Stock $0.19 per share; dividend yield 0%; expected terms 5 years; risk free interest rate: 1.31%; expected volatility of: 130.09%; and the expected price at which holders are likely to exercise their Warrants of $0.2431 per share.
	As of September 30, 2013 the fair value of the Series A and Series B Warrants was $2,643,449.  The fair value was determined using the Binomial Lattice model with the following assumptions: fair value of the Company’s Common Stock $0.09 per share; dividend yield 0%; expected terms 4.80 years; risk free interest rate: 1.39%; expected volatility of: 121.71%; and the expected price at which holders are likely to exercise their Warrants of $0.2431 per share.

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Sep. 30, 2013
Related Party Transactions [Abstract]	'
RELATED PARTY TRANSACTIONS	'
	NOTE G - RELATED PARTY TRANSACTIONS
	During the year ended September 30, 2012, the Company issued 22,924,513 shares of Common Stock in exchange for settlement of an aggregate of $925,000 related party convertible promissory notes and accrued interest.
	On June 21, 2012, Abarta Partners I, a partnership administered by Mr. Bitzer, one of the Company’s directors, for which his revocable
	trust is a partner, purchased 35,576,568 shares of our Common Stock at a purchase price of $0.04336 per share for gross proceeds of $1,542,600 in a private placement transaction.
	The Company acquired rights to certain software and intellectual property pursuant to an agreement it entered into with DivineRune Inc., a secure cloud-computing specialist, on January 25, 2012. DivineRune was issued a 3 year warrant to purchase one million shares of the Company’s common stock at an exercise price of $0.071 per share vesting in full on the first anniversary of the date of grant as compensation for a license to DivineRune’s patent portfolio. The Company will also share revenues on any future sales of products generated as a result of this agreement. The Company expects that the partnership will enhance and extend its core anti-counterfeiting, anti-diversion, and security systems into the digital track-and-trace sphere. James A. Hayward, the Company’s President, Chairman and Chief Executive Officer, and Yacov Shamash, a member of the Company’s  Board of Directors, were among the early investors in DivineRune.

CAPITAL_STOCK

CAPITAL STOCK	12 Months Ended
	Sep. 30, 2013
Stockholders' Equity Note [Abstract]	'
CAPITAL STOCK	'
	NOTE H - CAPITAL STOCK
	The Company is authorized to issue 1,350,000,000 shares of Common Stock, with a $0.001 par value per share, as the result of a vote of stockholders conducted on January 27, 2012, which effected an increase in the authorized shares of Common Stock from 800,000,000 shares to 1,350,000,000 shares.  In addition, the Company is authorized to issue 10,000,000 shares of preferred stock with a $0.001 par value per share.  As of September 30, 2013 and 2012, there were 786,526,955 and 646,182,550 shares of Common Stock issued and outstanding, respectively.
	Preferred and Common Stock Transactions during the Year Ended September 30, 2013:
	As part of the Purchase Agreements with Crede on November 29, 2012 and July 19, 2013, the Company sold an aggregate of $15,000,000 ($7,500,000 per agreement) of its securities. The total net proceeds received under these two financings were $14,635,000 ($15,000,000 gross proceeds, less investment fees of $365,000).  The table below summarizes the securities issued as part of these Purchase Agreements.
	Securities Issued	Initial Purchase Agreement				Second Purchase Agreement
		Shares issued		Price per share		Shares issued		Price per share
	Common Stock		10,752,688	$	0.186		10,695,187	$	0.187
	Series A Warrants		10,752,688	$	0.2232		10,695,187	$	0.2431
	Series B Warrants		29,569,862	$	0.2232		29,411,764	$	0.2431
	Series C Warrants		26,881,720	$	0.2232		26,737,967	$	0.2431
	Series A Preferred Stock		5,500	$	1,000		-	$	-
	Series B Preferred Stock		-	$	-		5,500	$	1,000
	The Series A and Series B Preferred contained weighted average anti-dilution protection.  The Series A and Series B Preferred did not accrue dividends except to the extent dividends were paid on the Common Stock.  The Company’s Common Stock was junior in rank to the Series A and Series B Preferred with respect to preferences as to dividends, distributions and payments upon the liquidation, dissolution and winding up of the Company.  The Series A and Series B Preferred generally had no voting rights except as required by law.  The Series A and Series B Preferred were converted into Common Stock as set forth below.
	Crede may exercise Series A and Series B Warrants by paying in cash or on a cashless basis by exchanging such Warrants for Common Stock using the Black-Scholes value.  In the event that the Common Stock trades at a price 25% or more above the exercise price of the Series A and Series B Warrants for a period of 20 consecutive days (with average daily dollar volume of Common Stock on the OTC Bulletin Board at least equal to $300,000), the Company may obligate Crede to exercise such Warrants for cash.
	Pursuant to registration rights agreements between the Company and Crede, the Company filed registration statements within 30 days of the Initial Closing of both purchase agreements.   The registration statements covered the resale of all shares of Common Stock issuable pursuant to the Purchase Agreements, including the shares of Common Stock underlying the Series A and Series B Preferred and Series A, B and C Warrants.  The Company has agreed to prepare and file amendments and supplements to the registration statements to the extent necessary to keep the registration statements effective for the period of time required under the Purchase Agreements.
	The Series A and Series B Preferred and the Series A, B and C Warrants each contain a 9.9% “blocker” so that in no event shall the Series A and Series B Preferred or any of the Series A, B and C Warrants be convertible or exercisable (including through the cashless exercise exchange provision) into or for Common Stock to the extent that such conversion or exercise would result in Crede having “beneficial ownership” (within the meaning of Section 13(d) of the Securities Exchange Act of 1934, as amended) of more than 9.9% of the Common Stock. Crede would, however, have the right from time to time to convert, exercise or exchange for shares of Common Stock, which over time would aggregate to greater than 9.9% beneficial ownership if all such shares of Common Stock so acquired had been held at one time by Crede.
	Crede has the right to participate in other equity or equity-linked financings completed by the Company for a period of 180 days from the date the registration statement went effective on July 30, 2013.
	In addition, the Company has agreed not to issue additional Common Stock or securities convertible into Common Stock at a price below the per share price issued to Crede under the Second Purchase Agreement, $0.187, or the market price of the Common Stock on the day before the registration statement was declared effective ($0.167), for a period of 180 days from the effective date of the registration statement, except for issuances (i) pursuant to acquisitions, joint ventures, license arrangements, leasing arrangements and other similar arrangements, (ii) to employees, consultants, directors and officers approved by the Board or pursuant to a plan approved by the Board, (iii) pursuant to one or more contracts entered into by the Company with third parties which would result in revenues to the Company during a three-month period equal to an annual run rate of $15 Million in revenues and (iv) pursuant to a contract entered into by the Company with a third party which would reasonably be expected to result in more than $3 Million in annual receivables.
	Until one year after the Second Closing, which occurred on July 31, 2013, the Company is prohibited from entering into any transaction to (i) sell any convertible securities at a conversion rate or other price that is generally based on and/or varies with the trading prices of the Company’s Common Stock at any time after the initial issuance of such convertible securities or (ii) sell securities at a future determined price, including, without limitation, an “equity line of credit” or an “at the market offering.”
	On January 8, 2013, Crede exercised its option and converted the Series A Preferred into 25,462,963 shares or the Company’s Common Stock at a conversion price of $0.216 per share and on April 25, 2013, Crede effected the cashless exercise of the Series A and Series B Warrants related to the Initial Purchase Agreement.  Also, on August 14, 2013, the Company exercised its option and converted the Series B Preferred into 42,307,692 shares of the Company’s Common Stock at a conversion price of $0.13 per share.  On January 22, 2013, the Company exercised its option to repurchase the Series C warrants related to the Initial Purchase Agreement and on August 14, 2013, the Company exercised its option to repurchase the Series C Warrants related to the Second Purchase Agreement for $50,000 and $10,000, respectively.

STOCK_OPTIONS_AND_WARRANTS

STOCK OPTIONS AND WARRANTS	12 Months Ended
	Sep. 30, 2013
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]	'
STOCK OPTIONS AND WARRANTS	'
	NOTE I - STOCK OPTIONS AND WARRANTS
	Warrants
	The following table summarizes the changes in warrants outstanding and the related prices for the shares of the Company’s Common Stock issued to non-employees of the Company.  These warrants were granted in lieu of cash compensation for services performed or financing expenses in connection with the sale of the Company’s Common Stock.
									Warrants
									Outstanding				Weighted						Exercisable
									Remaining				Average			Weighted			Weighted
	Exercise				Number				Contractual				Exercise			Average			Average
	Prices				Outstanding				Life (Years)				Price			Exercisable			Exercise Price
	$	0.04				3,000,000				1.92			$	0.04			3,000,000		$	0.04
	$	0.0441				510,784				3.79			$	0.0441			510,784		$	0.0441
	$	0.0475				3,789,489				4.79			$	0.0475			3,789,489		$	0.0475
	$	0.0553				226,081				4.27			$	0.0553			226,081		$	0.0553
	$	0.06				2,000,000				0.39			$	0.06			2,000,000		$	0.06
	$	0.071				1,000,000				1.32			$	0.071			1,000,000		$	0.071
	$	0.09				6,900,000				2.92			$	0.09			6,900,000		$	0.09
	$	0.179				100,000				2.1			$	0.179			100,000		$	0.179
	$	0.214				100,000				2.6			$	0.214			-		$	-
	$	0.2431				40,106,951				4.8			$	0.2431			40,106,951		$	0.2431
	$	0.5				1,300,000				0.12			$	0.5			1,300,000		$	0.5
						59,033,305				4.1			$	0.1976			58,933,305		$	0.1963
	Transactions involving warrants are summarized as follows:
			Number of				Weighted Average
			Shares				Price Per Share
	Balance, September 30, 2011			58,205,280			$	0.14
	Granted			1,075,000				0.071
	Exercised			(5,039,633	)			(0.045
	Cancelled or expired			(8,400,000	)			(0.161	)
	Balance at September 30, 2012			45,840,647			$	0.145
	Granted			134,249,218				0.233
	Exercised			(60,236,873	)			(0.170	)
	Cancelled or expired			(60,819,687	)			(0.265	)
	Balance,  September 30, 2013			59,033,305				0.196
	On October 31, 2011, warrants totaling 75,000 were issued in connection with services.  The warrants are exercisable for three years from the date of issuance at an exercise price of $0.07 per share with vesting immediately.  The fair value of the warrants of $1,363 was determined using the Black Scholes Option Pricing Model with the following assumptions: dividend yield $-0-, volatility of 157.69% and risk free rate from 0.41% and were charged to operations during the year ended September 30, 2012.
	On January 25, 2012, warrants totaling 1,000,000 were issued in connection with services.  The warrants are exercisable for three years from the date of issuance at an exercise price of $0.071 per share and will vest in full on the first anniversary of the date of grant.  The fair value of the warrants of $56,875 was determined using the Black Scholes Option Pricing Model with the following assumptions: dividend yield $-0-, volatility of 147.53% and risk free rate from 0.81% and were charged to operations during the year ended September 30, 2012.
	In September 2012, the Company issued an aggregate of 5,012,160 shares of Common Stock in settlement of 5,039,633 warrants exercised on a cashless basis.
	On November 7, 2012, 100,000 warrants were issued in connection with services. The warrants are exercisable on or after May 7, 2013 for three years at an exercise price of $0.179 per share. The fair value of the warrants of $13,238 was determined using the Black Scholes Option Pricing Model with the following assumptions: dividend yield $-0-, volatility of 129.56% and risk free rate from 0.36% and were charged to current period operations.
	On November 29, 2012, in connection the Initial Purchase Agreement, as described in Note H above, the Company issued an aggregate of 67,204,300 warrants to purchase the Company’s common stock exercisable for one to five years after defined date or events, at an exercise price of $0.2232 per share.
	In March 2013, the Company issued an aggregate of 1,500,000 shares of its common stock in connection with the exercise of warrants at an exercise price of $0.10 per share with net proceeds of $150,000.
	In April 2013, the Company issued 11,285,376 shares of its common stock in connection with the cashless exercise of 15,438,337 warrants to acquire the Company’s stock at a weighted average exercise price of $0.063 per share.
	In May 2013, the Company issued 2,418,971 shares of its common stock in connection with the cashless exercise of 2,975,956 warrants to acquire the Company’s stock at a weighted average exercise price of $0.042 per share.
	On May 7, 2013, 100,000 warrants were issued in connection with services. The warrants are exercisable on or after November 7, 2013 for three years at an exercise price of $0.214 per share.  The fair value of the warrants of $15,018 was determined using the Black Scholes Option Pricing Model with the following assumptions: dividend yield $-0-, volatility of 119.72% and risk free rate from 0.35% and were charged to current period operations.
	As described in Note H above, on January 22, 2013, the Company exercised its option to repurchase 26,881,720 Series C Warrants issued to Crede under the Initial Purchase Agreement for $50,000.  On April 25, 2013, under the Initial Purchase Agreement, Crede effected the cashless exercise of 10,752,688 Series A Warrants and 29,569,892 Series B Warrants, and the Company thereupon issued to Crede an aggregate of 31,257,045 shares of its Common Stock.
	On July 19, 2013, in connection the Second Purchase Agreement, as described in Note H above, the Company issued an aggregate of 66,844,918 warrants to purchase the Company’s common stock exercisable for one to five years after defined date or events, at an exercise price of $0.2431 per share.
	On August 14, 2013, the Company exercised its option to repurchase 26,737,967 Series C Warrants issued to Crede under the Second Purchase Agreement for $10,000, as described in Note H above.
	Employee Stock Options
	In 2005, the Board of Directors and the holders of a majority of the outstanding shares of Common Stock approved the 2005 Incentive Stock Plan. In 2007, 2008 and 2012, the Board of Directors and holders of a majority of the outstanding shares of Common Stock approved various increases in the number of shares of Common Stock that can be issued as stock awards and stock options thereunder to an aggregate 350,000,000 shares and the number of shares of Common Stock that can be covered by awards made to any participant in any calendar year to 50,000,000 shares.
	The 2005 Incentive Stock Plan is designed to retain directors, executives, and selected employees and consultants by rewarding them for making contributions to our success with an award of options to purchase shares of Common Stock.  As of September 30, 2013, a total of 10,175,000 shares have been issued and options to purchase 125,208,825 shares have been granted under the 2005 Incentive Stock Plan.
	The following table summarizes the changes in options outstanding and the related prices for the shares of the Company’s Common Stock issued to employees of the Company under the 2005 Incentive Stock Plan:
		Options Outstanding										Options Exercisable
		Exercise		Number				Weighted Average				Weighted Average			Number			Weighted
		Prices		Outstanding				Remaining				Exercise Price			Exercisable			Average
								Contractual										Exercise Price
								Life (Years)
	$	0.05			24,000,000				1.65			$	0.05			24,000,000		$	0.05
	$	0.0585			50,000,000				4.79			$	0.0585			50,000,000		$	0.0585
	$	0.06			30,000,000				1.76			$	0.06			30,000,000		$	0.06
	$	0.065			634,825				3.18			$	0.065			634,825		$	0.065
	$	0.068			4,770,000				3.17			$	0.068			4,770,000		$	0.068
	$	0.07			2,850,000				1.67			$	0.07			1,900,000		$	0.07
	$	0.09			1,500,000				2.92			$	0.09			1,500,000		$	0.09
	$	0.11			5,400,000				4.71			$	0.11			5,400,000		$	0.11
	$	0.1799			2,099,367				4.17			$	0.1799			-		$	-
	$	0.193			100,000				4.75			$	0.193			-		$	-
$	0.2			100,000				4.63			$	0.2			-		$	-
				121,454,192				3.23			$	0.063			118,204,825		$	0.0605
Transactions involving stock options issued to employees are summarized as follows:
		Number of				Weighted Average					Aggregate Intrinsic
		Shares				Exercise Price Per Share					Value
Outstanding at October 1, 2011			120,650,000			$	0.06
Granted			6,558,825				0.067
Exercised			(500,000	)			(0.08	)
Cancelled or expired			(1,500,000	)			(0.08	)
Outstanding at September 30, 2012			125,208,825			$	0.06
Granted			2,299,367				0.181
Exercised			(5,979,000	)			(0.042	)
Cancelled or expired			(75,000	)			(0.060	)
Outstanding at September 30, 2013			121,454,192			$	0.063
Vested at September 30, 2013			118,204,825							$	0.136
Non-vested at September 30, 2013			3,429,367							$	0.055
On November 30, 2011, the Company granted an aggregate of 5,724,000 options to purchase the Company’s Common Stock at an exercise price of $0.068 per share for five years to directors with immediate vesting.  The fair value of options was determined using the Black-Scholes Option Pricing Model with the following assumptions: dividend yield $-0-, volatility of 156.65% and risk free rate of 0.96%.
On December 6, 2011, the Company granted an aggregate of 634,825 options to purchase the Company’s Common Stock at an exercise price of $0.065 per share for five years to two directors with immediate vesting.  The fair value of options was determined using the Black-Scholes Option Pricing Model with the following assumptions: dividend yield $-0-, volatility of 156.29% and risk free rate of 0.94%.
On February 8, 2012, the Company granted 100,000 options to purchase the Company’s Common Stock at an exercise price of $0.07 per share for five years to an employee with vesting at 25% each anniversary for the next four years.  The fair value of options was determined using the Black-Scholes Option Pricing Model with the following assumptions: dividend yield $-0-, volatility of 152.56% and risk free rate of 0.82%.
On March 16, 2012, the Company granted 100,000 options to purchase the Company’s Common Stock at an exercise price of $0.06 per share for five years to an employee with vesting at 25% each anniversary for the next four years.  The fair value of options was determined using the Black-Scholes Option Pricing Model with the following assumptions: dividend yield $-0-, volatility of 149.81% and risk free rate of 1.13%.
On September 24, 2012, the Company issued 349,114 shares of Common Stock in settlement of 500,000 options exercised on a cashless basis and the remaining 1,500,000 options expired.
On November 30, 2012, the Company granted an aggregate of 2,099,367 options to non-employee board of director members (except Mr. Catenacci) under the 2005 Incentive Stock Plan. The options are exercisable at $0.1799 per share for five years, vesting one year from the date of issuance. The fair value of options was determined using the Black Scholes Option Pricing Model with the following assumptions: dividend yield $-0-, volatility of 146.33% and risk free rate of 0.82%.
On May 12, 2013, the Company granted an aggregate of 100,000 options to an employee under the 2005 Incentive Stock Plan.  The options are exercisable at $0.20 per share for five years, vesting at 25% each anniversary for the next four years. The fair value of the options was determined using the Black Scholes Option Pricing Model with the following assumptions:  dividend yield $-0-, volatility of 117.57% and risk free rate of 0.60%.
On May 15, 2013 the Company extended the term of 5,400,000 options that were set to expire to June 16, 2018. The Company recorded $408,605 of stock compensation expense for the year ended September 30, 2013 in connection with this modification as the incremental difference between fair value of the stock options immediately before and after modification.
On July 2, 2013 the Company granted an aggregate of 100,000 options to an employee under the 2005 Incentive Stock Plan.  The options are exercisable at $0.193 per share for five years, vesting at 25% each anniversary for the next four years.  The fair value of the options was determined using the Black Scholes Option Pricing Model with the following assumptions:  dividend yield $-0-, volatility of 114% and risk free interest rate of 1.01%.
During the year ended September 30, 2013, the Company issued 4,639,483 shares of its Common Stock in connection with the cashless exercise of 5,954,000 options to acquire the Company’s stock at a weighted average of $.053 per share. The Company also issued 25,000 shares of its Common Stock in connection with the exercise of 25,000 options at $0.06 per share.
In accordance with his resignation agreement dated August 20, 2013, Mr. Jensen, the former Chief Financial Officer of the Company shall have one year from his resignation date to exercise his 20,500,000 vested options. There was no expense associated with this modification.
See Note M for details of issuances subsequent to the twelve months ended September 30, 2013.
The Company recorded $1,926,129 (including the stock option modification) and $1,953,844 as stock compensation expense for the years ended September 30, 2013 and 2012, respectively for the vesting portion of all employee options outstanding. As of September 30, 2013, unrecorded compensation cost related to non-vested awards was $107,462, which is expected to be recognized through 2018.

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
INCOME TAXES	'
	NOTE J - INCOME TAXES
	The Company utilizes ASC 740 “Income Taxes”, which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the consolidated financial statement or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between consolidated financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Temporary differences between taxable income reported for financial reporting purposes and income tax purpose include, but are not limited to, accounting for intangibles, warrants, equity based compensation and depreciation and amortization.
	As of September 30, 2013, the Company had available for U.S federal income tax purposes net operating loss carryovers of approximately $46,300,000, which expire beginning the fiscal tax year of 2022. The net operating loss carryovers may be subject to limitations under Internal Revenue Code due to significant changes in the Company’s ownership. The Company has provided a full valuation allowance against the full amount of the net operating loss benefit, since, in the opinion of management, based upon the earnings history of the Company it is more likely than not that the benefits will not be realized.
	The income tax provision (benefit) for the years ended September 30, 2013 and 2012 consists of the following:
		2013			2012
	Federal:
	Current	$	-		$	-
	Deferred		2,955,000			1,422,000
			2,955,000			1,422,000
	State and local:
	Current		-			-
	Deferred		407,000			196,000
			407,000			196,000
	Change in valuation allowance		(3,362,000	)		(1,618,000	)
	Income tax provision (benefit)	$	-		$	-
	The provision for income taxes differ from the amount of income tax determined by applying the applicable U.S statutory rate to losses before income tax expense for the years ended September 30, 2013 and 2012 as follows:
		September 30,
		2013			2012
	Statutory federal income tax rate		(34.00	%)		(34.00	%)
	Statutory state and local income tax rate (7.1%), net of federal benefit		(4.69	%)		(4.69	%)
	Stock based compensation		3.27	%		10.74	%
	Depreciation and amortization		(0.12	%)		(0.28	%)
	Amortization of debt discount		0	%		2.92	%
	Change in valuation allowance		35.54	%		25.31	%
	Effective tax rate		0	%		0	%
	Deferred income taxes result from temporary differences in the recognition of income and expenses for financial reporting purposes and for tax purposes. The tax effect of these temporary differences representing deferred tax asset and liabilities result principally from the following:
		September 30,
		2013			2012
	Deferred tax assets (liabilities):
	Stock based compensation	$	578,000		$	768,000
	Depreciation and amortization		(21,000	)		(20,000	)
	Amortization of debt discount		-			209,000
	Net operating loss carry forward		17,913,000			14,551,000
	Less: valuation allowance		(18,470,000	)		(15,508,000	)
	Net deferred tax asset	$	-		$	-
	The provisions of ASC 740 require companies to recognize in their financial statements the impact of a tax position if that position is more likely than not to be sustained upon audit, based upon the technical merits of the position. ASC 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken on a tax return. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods and disclosure.
	Management does not believe that the Company has any material uncertain tax positions requiring recognition or measurement in accordance with the provisions of ASC 740. Accordingly, the adoption of these provisions of ASC 740 did not have a material effect on the Company’s consolidated financial statements. The Company’s policy is to record interest and penalties on uncertain tax positions, if any, as income tax expense.
	All tax years for the Company remain subject to future examinations by the applicable taxing authorities.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	NOTE K- COMMITMENTS AND CONTINGENCIES
	Operating leases
	On June 14, 2013, the Company entered into an operating lease agreement for its new corporate headquarters located in Stony Brook, New York.  The lease is for a 30,000 square foot building.  The term of the lease commenced on June 15, 2013 and expires on May 31, 2016, with the option to extend the lease for two additional three-year periods.  The base rent during the initial lease term is $449,142 per annum.  This new location replaces a lesser amount of space leased by the Company in an adjacent building, which was for corporate use.     The Company also has operating leases for a laboratory in Huddersfield, England, which is currently inactive and Calverton, New York.  The leases for both of these spaces are currently month to month. Total lease rental expenses for years ended September 30, 2013 and 2012 were $352,867 and $244,192, respectively.
	Future minimum rental payments (excluding real estate tax and maintenance costs) as of September 30, 2013 are as follows:
	2014	$	450,617
	2015		449,142
	2016		299,428
	Total		1,199,187
		$
	Employment and Consulting Agreements
	Employment agreements
	On July 11, 2011, the Company’s Board of Directors approved the terms of employment for each of James A. Hayward, the Company’s Chief Executive Officer (“CEO”), and Kurt H. Jensen, the Company’s former Chief Financial Officer.
	In connection with his employment agreement, Dr. Hayward was granted options to purchase 40 million shares of the Company’s Common Stock at an exercise price per share equal to the average of the bid and asked prices of the Company’s Common Stock on the Over The Counter Market Group (the “OTCQB”) Bulletin Board on the date of grant ($0.0585).  The option will vest as follows: 25% on the grant date, and 37.5% on each of the next two anniversaries of the grant date, subject to Dr. Hayward’s continuous employment.  If Company’s revenues for any fiscal quarter increase by more than $1 million over the prior fiscal quarter, then the vesting date for the next 37.5% tranche will be accelerated.  Exercisability of options for the 40 million shares was conditioned upon stockholder approval of an amendment of the Company’s 2005 Incentive Stock Plan made by the Board of Directors increasing the aggregate and individual limits on the shares of Company Common Stock issuable under the Plan.  The Company also granted 15 million shares of the Company’s Common Stock to Dr. Hayward.
	In connection with his employment agreement, Mr. Jensen was granted options to purchase 10 million shares of the Company’s Common Stock at an exercise price per share equal to the average of the bid and asked prices of the Company’s Common Stock on the Over The Counter Market Group (the “OTCQB”) on the date of grant of grant of ($0.0585).  The option will vest as follows: 25% on the grant date, and 37.5% on each of the next two anniversaries of the grant date, subject to Mr. Jensen’s continuous employment.  If Company’s revenues for any fiscal quarter increase by more than $1 million over the prior fiscal quarter, then the vesting date for the next 37.5% tranche will be accelerated.   On August 20, 2013, Mr. Jensen resigned as Chief Financial Officer of the Company. According to his separation agreement, Mr. Jensen will receive payment of his base salary through December 31, 2013 and he shall have one year from his resignation date to exercise his 20,500,000 vested options.  As of September 30, 2013 approximately $79,000 was accrued related to Mr. Jensen’s resignation agreement.
	Litigation
	From time to time, the Company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business.  When the Company is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, the Company will record a liability for the loss. In addition to the estimated loss, the recorded liability includes probable and estimable legal costs associated with the claim or potential claim. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm the Company’s business.
	Demodulation, Inc. v. Applied DNA Sciences, Inc., et al. (Civil Action No. 2:11-00296-WJM-MF, District of New Jersey):
	On May 18, 2011, the Company was served with a complaint in a lawsuit brought by Demodulation, Inc. against the Company, Corning Incorporated, Alfred University, and Alfred Technology Resources, Inc.  On July 8, 2011, the Company filed a motion to dismiss the complaint.  In response, on August 3, 2011, Demodulation filed an amended complaint.  Demodulation alleged that it was unable to bring its microwire technology to market due to the wrongful acts of defendants, who allegedly conspired to steal Demodulation’s trade secrets and other intellectual property and to interfere in its business opportunities.  Of the 17 claims alleged in the amended complaint, five were asserted against the Company, including alleged misappropriation of trade secrets, antitrust violations, civil RICO, and patent infringement.  The Company believes these claims are without merit.
	On January 27, 2012, the Company filed a motion to dismiss the amended complaint for failure to state a claim and on other grounds.  On December 12, 2012, the Court entered an order on the Company’s motion to dismiss.  The Court granted in part and denied in part the Company’s motion, dismissing four out of the five claims asserted against the Company, without prejudice, leaving only the patent infringement claim.  Subsequently, the parties stipulated to sever the patent infringement claim against the Company from the claims against the other defendants.  The Court entered an order severing the patent claim on February 20, 2013, and terminated the main lawsuit against the Company.  Demodulation may seek to re-file its patent claim as a separate action, but to date has not done so.  If Demodulation re-files its action, the Company intends to vigorously defend the action.  We are unable to express an opinion with respect to the likelihood of an unfavorable outcome or to estimate the amount or range of potential loss if the outcome should be unfavorable, should Demodulation re-file its action, or whether it will re-file it.
	SmartWater, Ltd. v. Applied DNA Sciences, Inc. (Civil Action No. 12-05731-JS-AKT, Eastern District of New York)
	On June 6, 2012, a complaint for patent infringement was filed against the Company by SmartWater, Ltd. in the United States District Court for the District of Massachusetts.  It alleged that the Company infringed one or more claims under two of SmartWater’s patents by selling or offering for sale, manufacturing and using certain of the Company’s products, by inducing others to infringe and by contributing to infringement by others.  Prior to serving the complaint, on August 24, 2012, SmartWater voluntarily dismissed the complaint and refiled a similar complaint in the United States District Court for the Southern District of Florida, No. 12-611660-DMM.  On August 30, 2012, SmartWater served the Company with the complaint.  The refiled complaint seeks injunctive relief with respect to one of the patents as well as awards of damages and attorneys’ fees with respect to the alleged infringement of both patents.
	The Company filed a motion to dismiss and a motion to transfer the action to the United States District Court for the Eastern District of New York.  On November 19, 2012, the Court granted the Company’s motion to transfer.  Following the transfer, but prior to a decision on the Company’s motion to dismiss, on June 26, 2013, SmartWater moved for leave to file an amended complaint asserting additional allegations in support of its claims.  By memorandum and order dated September 27, 2013, the Court granted in part, and denied in part, SmartWater’s motion.  The Court held that SmartWater had adequately stated claims for direct infringement of both patents at issue, but had not adequately stated claims for contributory infringement of the patents, or induced infringement with respect to one of the patents, and therefore dismissed them.  On October 10, 2013, the Company filed its (i) answer to the amended complaint, as modified by the Court’s September 27, 2013 order, and (ii) counterclaims.  On October 31, 2013, the Company filed an amended answer and counterclaims.  The Company and SmartWater have filed motions for reconsideration of a portion of the Court’s order.  These motions seek a determination of whether SmartWater’s remaining claim for induced infringement of one of the patents should survive, or be dismissed because the patent expired before the Company had notice of it.   In addition, the parties are now engaged in discovery.
	The Company believes the claims are without merit and intends to defend the action vigorously.  We are unable to express our opinion with respect to the likelihood of an unfavorable outcome or to estimate the amount or range of potential loss if the outcome should be unfavorable.

FAIR_VALUE

FAIR VALUE	12 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
FAIR VALUE	'
	NOTE L - FAIR VALUE
	The carrying value of cash, accounts receivable, accounts payable and accrued expenses approximate estimated fair values because of their short maturities.
	The carrying value of the warrant liability is determined using the Binomial Lattice model option pricing model as described in Note B. Certain assumptions used in the calculation of the warrants liability represent level-3 unobservable inputs. The Company did not have any assets or liabilities categorized as Level 1 or 2 as of September 30, 2013.
	The following table summarizes the activity of Level 3 inputs measured on a recurring basis:
	Fair Value Measurements of Common Stock Warrants Using Significant Unobservable Inputs (Level 3)	Year Ended September 30,
		2013			2012
	Balance at October 1,	$	—		$	—
	Issuance of Series A and B Warrants		2,461,856			—
	Adjustment resulting from change in value recognized in earnings (a)		7,508,146			—
	Reclassification to equity upon exercise		(7,326,553	)		—
	Balance at September 30,	$	2,643,449		$	—
	(a) Adjustment resulting from change in fair value is the amount of total gains or losses for the period attributable to the change in unrealized gains or losses relating to liabilities held at the reporting date. The unrealized gain or loss is recorded in change in fair value of warrant liability in the accompanying condensed consolidated statements of operations.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Sep. 30, 2013
Subsequent Events [Abstract]	'
SUBSEQUENT EVENTS	'
	NOTE M – SUBSEQUENT EVENTS
	In accordance with FASB ASC 855, “Subsequent Events,” the Company has evaluated subsequent events through the date of filing.
	On October 14, 2013, Karol Gray commenced employment with the Company as the Chief Financial Officer. Pursuant to an offer letter, Ms. Gray will be an at-will employee and will be paid an annual starting salary of $336,000. In addition, after six months employment, she will be granted a five year option pursuant to the Company’s 2005 Incentive Stock Plan to purchase up to 2,000,000 shares of the Company’s Common Stock at the fair market value on the date of grant, vesting in four equal annual increments beginning on the first anniversary of the date of grant.
	On December 16, 2013, Crede effected the cashless exercise of 10,695,187 Series A Warrants and 7,000,000 Series B Warrants, and the Company thereupon issued to Crede an aggregate of 18,823,073 shares of its Common Stock.
	Subsequent Option Grants
	On October 14, 2013, the Company granted an aggregate of 7,928,000 options to purchase the Company’s Common Stock at an exercise price of $0.0886 per share for five years to employees, 5,928,000 of these options vest at 25% each anniversary for the next four years and 2,000,000 of these options vest immediately.
	On October 17, 2013, the Company granted, Dr. James A. Hayward, Chairman, CEO and President and Mr. Ming-Hwa Liang, Chief Technology Officer and Secretary of the Company options to purchase 50,000,000 and 3,000,000 shares of the Company’s Common Stock, respectively, at an exercise price of $0.097 per share for five years to employees with vesting at 25% each anniversary for the next four years.   Also on October 17, 2013, the Company granted an aggregate of 3,777,780 options to purchase the Company’s Common Stock at an exercise price of $0.0886 per share for five years to nonemployee directors with immediate vesting.
	On November 28, 2013, the Company granted 250,000 options to purchase the Company’s Common Stock at an exercise price of $0.1160 per share for five years to an employee with vesting at 25% each anniversary for the next four years.
	On December 2, 2013, the Company granted 2,000,000 options to purchase the Company’s Common Stock at an exercise price of $0.1170 per share for five years to the Chief Information Officer with vesting at 25% each anniversary for the next four years.
	On December 10, 2013, the Company granted an aggregate of 2,126,000 options to purchase the Company’s Common Stock at an exercise price of $0.1360 per share for five years to employees, with immediate vesting.

SUMMARY_OF_ACCOUNTING_POLICIES1

SUMMARY OF ACCOUNTING POLICIES (Policies)	12 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Business and Basis of Presentation	'
	Business and Basis of Presentation
	On September 16, 2002, Applied DNA Sciences, Inc. (the “Company”) was incorporated under the laws of the State of Nevada.  Effective December 17, 2008, the Company reincorporated from the State of Nevada to the State of Delaware.  The Company is principally devoted to developing DNA embedded biotechnology security solutions in the United States and Europe.  To date, the Company has generated limited sales revenues from services and products; it has incurred expenses and has sustained losses.  Consequently, its operations are subject to all risks inherent in the establishment of an early stage company.  For the period from inception through September 30, 2013, the Company has accumulated losses of $186,693,611.
	The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Applied DNA Operations Management, Inc., APDN (B.V.I.) Inc. and Applied DNA Sciences Europe Limited, which currently have no operations.  Significant inter-company transactions have been eliminated in consolidation.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect certain reported amounts and disclosures.  Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources.  The most complex and subjective estimates include; recoverability of long-lived assets, including the value assigned to intangible assets and property and equipment, fair value calculations for warrants, contingencies and allowances for doubtful accounts.  Management reviews its estimates on a regular basis and the effects of any material revisions are reflected in the consolidated financial statements in the period they are deemed necessary.  Accordingly, actual results could differ from those estimates.
Reclassifications	'
	Reclassifications
	Certain reclassifications have been made in prior year’s financial statements to conform with the current year’s financial statements’ presentation.
Revenue Recognition	'
	Revenue Recognition
	The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) 605, Revenue Recognition (“ASC 605”).  ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and/or service has been performed; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured.  Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered or services provided and the collectability of those amounts.  Provisions for allowances and other adjustments are provided for in the same period the related sales are recorded.  The Company defers any revenue for which the product has not been delivered, service has not been provided, or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered, the service has been provided, or no refund will be required.  At September 30, 2013 and 2012, the Company recorded deferred revenue of $148,503 and $0, respectively.
	Revenue arrangements with multiple components are divided into separate units of accounting if certain criteria are met, including whether the delivered component has stand-alone value to the customer.  Consideration received is allocated among the separate units of accounting based on their respective selling prices.  The selling price for each unit is based on vendor-specific objective evidence, or VSOE, if available, third party evidence if VSOE is not available, or estimated selling price if neither VSOE nor third party is available.  The applicable revenue recognition criteria are then applied to each of the units.
	Revenue for a Government contract award, which supports our development efforts on specific projects is recognized as milestones are achieved as per the contract.  The Company recognized revenue of $100,000 from this contract during the year ended September 30, 2013.
Cash Equivalents	'
	Cash Equivalents
	For the purpose of the accompanying consolidated financial statements, all highly liquid investments with a maturity of three months or less are considered to be cash equivalents.
Accounts Receivable	'
	Accounts Receivable
	The Company provides an allowance for doubtful accounts equal to the estimated uncollectible amounts.  The Company’s estimate is based on historical collection experience and a review of the current status of trade accounts receivable.  It is reasonably possible that the Company’s estimate of the allowance for doubtful accounts will change.  At September 30, 2013 and 2012, the Company has an allowance for doubtful accounts of $62,415 and $0, respectively.  The Company writes-off receivables that are deemed uncollectible.  The Company wrote-off $15,000 and $0 of accounts receivable that was not previously reserved for during the year ended September 30, 2013 and 2012, respectively.
Income Taxes	'
	Income Taxes
	The Company accounts for income taxes in accordance with ASC 740, Income Taxes (“ASC 740-10”) which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statement or tax returns.  Under this method, deferred tax liabilities and assets are determined based on the difference between financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Temporary differences between taxable income reported for financial reporting purposes and income tax purposes include, but not limited to, accounting for intangibles, warrants, equity based compensation and depreciation and amortization.
	The Company evaluates the recoverability of deferred tax assets and establishes a valuation allowance when it is more likely than not that some portion or all of the deferred tax asset will not be realized.  During the years ended September 30, 2013 and 2012, the Company incurred losses from operations. Based upon these results and the trends in the Company’s performance projected for fiscal year 2014, it is more likely than not that the Company will not realize any benefit from the deferred tax assets recorded by the Company in previous periods.  Management makes judgments as to the interpretation of tax laws that might be challenged upon an audit and cause changes to previously estimates of tax liability.  In management’s opinion, adequate provisions for income taxes have been made for all years.  If actual taxable income by tax jurisdiction varies from estimates, additional allowances or reversals of reserves may be necessary.  The Company has identified its federal tax return and its state tax return in New York as “major” tax jurisdictions.  Based on the Company’s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company consolidated financial statements.
	The Company’s evaluation was performed for tax years 2009 through 2012.  The Company believes that its income tax positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position.  It is the Company’s policy to accrue interest and penalties on unrecognized tax benefits as components of income tax provision.  The Company did not have any accrued interest or penalties as of September 30, 2013 and 2012.
Property Plant and Equipment	'
	Property Plant and Equipment
	Property Plant and equipment are stated at cost and depreciated using the straight line method over their estimated useful lives.  The estimated useful for computer equipment, lab equipment and furniture is 3 to 5 years and leasehold improvements are amortized over the shorter of their useful life or the lease terms.  Property plant and equipment consist of:
		September 30,
		2013		2012
	Computer equipment	$	43,555	$	33,464
	Lab equipment		657,735		296,904
	Furniture		164,997		132,435
	Leasehold improvements		239,337		-
	Total		1,105,624		462,803
	Accumulated depreciation		409,629		251,958
	Property and equipment, net	$	695,995	$	210,845
	Depreciation expense for the years ended September 30, 2013 and 2012 were $157,671 and $41,096, respectively.
Impairment of Long-Lived Assets	'
	Impairment of Long-Lived Assets
	The Company accounts for its long-lived assets in accordance with ASC 360, Property, Plant and Equipment (“ASC 360”).  ASC 360 requires that long-lived assets and certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  The Company evaluates its long lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a forecasted inability to achieve break-even operating results over an extended period.  The Company evaluates the recoverability of long-lived assets based upon forecasted undiscounted cash flows.  Should impairment in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset.  ASC 360 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less costs to sell. For the years ended September 30, 2013 and 2012, the Company recognized impairment charges of $114,730 and $0, respectively related to certain intellectual property.
Segment Information	'
	Segment Information
	The Company follows the provisions of ASC 280, Segment Reporting (“ASC 280-10”).  ASC 280 establishes standards for reporting information regarding operating segments in annual financial statements and requires selected information for those segments to be presented in interim financial reports issued to stockholders.  ASC 280 also establishes standards for related disclosures about products and services and geographic areas.  Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision- making group, in making decisions how to allocate resources and assess performance.  The information disclosed herein, materially represents all of the financial information related to the Company’s single principal operating segment.
Net Loss per Share	'
	Net Loss per Share
	The Company presents loss per share utilizing a dual presentation of basic and diluted loss per share.  Basic loss per share includes no dilution and has been calculated based upon the weighted average number of common shares outstanding during the period.  Dilutive common stock equivalents consist of shares issuable upon the exercise of the Company’s stock options and warrants.
	For the years ended September 30, 2013 and 2012, common stock equivalent shares are excluded from the computation of the diluted loss per share as their effect would be anti-dilutive.
	Fully diluted shares outstanding were 839,583,895 and 692,328,470 for the years ended September 30, 2013 and 2012, respectively.
Stock Based Compensation	'
	Stock Based Compensation
	The Company accounts for stock-based compensation in accordance with ASC 718, Compensation (“ASC 718”).  ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statement of operations based on their fair values.  Under the provisions of ASC 718, stock-based compensation costs is measured at the grant date, based on the fair value of the award, and is recognized as expense over the employee’s requisite service period (generally the vesting period of the equity grant).  The fair value of the Company’s common stock options are estimated using the Black Scholes option-pricing model with the following assumptions:  expected volatility, dividend rate, risk free interest rate and the expected life.   The Company expenses stock-based compensation by using the straight-line method. In accordance with ASC 718, excess tax benefits realized from the exercise of stock-based awards are classified in cash flows from financing activities. The future realization of the reserved deferred tax assets related to these tax benefits associated with the exercise of stock options will result in a credit to additional paid in capital if the related tax deduction reduces taxes payable. The Company has elected the “with and without approach” regarding ordering of windfall tax benefits to determine whether the windfall tax benefit did reduce taxes payable in the current year. Under this approach, the windfall tax benefit would be recognized in additional paid-in-capital only if an incremental tax benefit is realized after considering all other benefits presently available.  Stock-based compensation expense recognized under ASC 718 for the years ended September 30, 2013 and 2012 was $1,926,129 and $1,953,844, respectively.
Concentrations	'
	Concentrations
	Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables.  The Company places its cash and temporary cash investments with high credit quality institutions.  At times, such investments may be in excess of the FDIC insurance limit.
	No customers represented greater than 10% of the Company’s total revenues for the year ended September 30, 2013. The Company’s revenues earned from sale of products and services for the year ended September 30, 2012 included an aggregate of 54% from two customers of the Company’s total revenues.  Three and two customers accounted 43% and 54% of the Company’s total accounts receivable at September 30, 2013 and 2012, respectively.
Research and Development	'
	Research and Development
	The Company accounts for research and development costs in accordance with the ASC 730, Research and Development (“ASC 730”).  Under ASC 730, all research and development costs must be charged to expense as incurred.  Accordingly, internal research and development costs are expensed as incurred.  Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved.  Company-sponsored research and development costs related to both present and future products are expensed in the period incurred.  The Company incurred research and development expenses of $692,480 and $432,669 for the years ended September 30, 2013 and 2012, respectively.
Advertising	'
	Advertising
	The Company follows the policy of charging the costs of advertising to expense as incurred.  The Company charged to operations $196,762 and $97,877 as advertising costs for the years ended September 30, 2013 and 2012, respectively.
Intangible Assets	'
	Intangible Assets
	The Company amortizes its intangible assets using the straight-line method over their estimated period of benefit.  The estimated useful life for patents is five years while other intellectual property uses a seven year useful life.  The Company periodically evaluates the recoverability of intangible assets and takes into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists.  All of the Company’s intangible assets are subject to amortization.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The Company’s financial instruments are primarily composed of cash, accounts receivable, accounts payable and accrued liabilities, and warrants. The fair value of cash, accounts receivable, accounts payable and accrued liabilities, as reflected in the consolidated balance sheet, approximate its fair value due to the short-term maturity of these instruments.
	The valuation techniques utilized are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect internal market assumptions. These two types of inputs create the following fair value hierarchy:
	Level 1 – Quoted prices in active markets for identical assets or liabilities.
	Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related asset or liabilities.
	Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of assets or liabilities.
	The Company utilizes observable market inputs (quoted market prices) when measuring fair value whenever possible.
	For fair value measurements categorized within Level 3 of the fair value hierarchy, the Company’s accounting and finance department, who report to the Chief Financial Officer, determine its valuation policies and procedures. The development and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s accounting and finance department and are approved by the Chief Financial Officer.
	As of September 30, 2013, there were no transfers in or out of Level 3 from other levels.
	The fair value of each warrant is estimated using the Binomial Lattice option valuation model. Significant observable and unobservable inputs include stock price, exercise price, annual risk free rate, term, and expected volatility, and are classified within Level 3 of the valuation hierarchy. An increase or decrease in volatility, in isolation, can significantly increase or decrease the fair value of the warrant. See Note L.
Recently Adopted Accounting Principles	'
	Recently Adopted Accounting Principles
	There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s consolidated financial position, results of operations or cash flows
Subsequent Events	'
	Subsequent Events
	The Company has evaluated events that occurred subsequent to the balance sheet date and through the date the financial statements were available to be issued. Other than those events disclosed in the notes to these consolidated financial statements, management concluded that no additional subsequent events required disclosure in these consolidated financial statements.

SUMMARY_OF_ACCOUNTING_POLICIES2

SUMMARY OF ACCOUNTING POLICIES (Tables)	12 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Schedule of property, plant and equipment	'
		September 30,
		2013		2012
	Computer equipment	$	43,555	$	33,464
	Lab equipment		657,735		296,904
	Furniture		164,997		132,435
	Leasehold improvements		239,337		-
	Total		1,105,624		462,803
	Accumulated depreciation		409,629		251,958
	Property and equipment, net	$	695,995	$	210,845

INTANGIBLE_ASSETS_Tables

INTANGIBLE ASSETS (Tables)	12 Months Ended
	Sep. 30, 2013
Intangible Assets Disclosure [Abstract]	'
Schedule of intangible assets acquired and their carrying values	'
		2013			2012
	Trade secrets and developed technologies (Weighted average life of 7 years)	$	-		$	3,775,889
	Patents (Weighted average life of 5 years)		-			34,257
	Intellectual property (Weighted average life of 5 years)		584,080			-
	Total identifiable intangible assets-Gross carrying value:		584,080			3,810,146
	Less:
	Accumulated amortization		(48,674	)		(3,810,146	)
	Impairment charges		(114,730	)		-
	Intangible assets, net	$	420,676		$	-
Schedule of estimated amortization expense of the intangible assets for each of the five succeeding years	'
		Amount
	2014	$	90,145
	2015		90,145
	2016		90,145
	2017		90,145
	2018		60,096
	Total	$	420,676

ACCOUNTS_PAYABLE_AND_ACCRUED_L1

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)	12 Months Ended
	Sep. 30, 2013
Payables and Accruals [Abstract]	'
Schedule of accounts payable and accrued liabilities	'
		2013		2012
	Accounts payable	$	641,302	$	473,060
	Accrued consulting fees		102,500		102,500
	Accrued salaries payable		220,175		16,449
	Other accrued expenses		3,000		-
	Total	$	966,977	$	592,009

WARRANT_LIABILITY_Tables

WARRANT LIABILITY (Tables)	12 Months Ended
	Sep. 30, 2013
Warrant Liability [Abstract]	'
Schedule of details of Series A, B and C Warrants allowing Crede to purchase the shares of Common Stock	'
	Securities Issued	Initial Purchase Agreement				Second Purchase Agreement
		Shares issued		Price per share		Shares issued		Price per share
	Series A Warrants		10,752,688	$	0.2232		10,695,187	$	0.2431
	Series B Warrants		29,569,862	$	0.2232		29,411,764	$	0.2431
	Series C Warrants		26,881,720	$	0.2232		26,737,967	$	0.2431

CAPITAL_STOCK_Tables

CAPITAL STOCK (Tables)	12 Months Ended
	Sep. 30, 2013
Stockholders' Equity Note [Abstract]	'
Schedule of summary of the securities issued as part of the purchase agreements	'
	Securities Issued	Initial Purchase Agreement				Second Purchase Agreement
		Shares issued		Price per share		Shares issued		Price per share
	Common Stock		10,752,688	$	0.186		10,695,187	$	0.187
	Series A Warrants		10,752,688	$	0.2232		10,695,187	$	0.2431
	Series B Warrants		29,569,862	$	0.2232		29,411,764	$	0.2431
	Series C Warrants		26,881,720	$	0.2232		26,737,967	$	0.2431
	Series A Preferred Stock		5,500	$	1,000		-	$	-
	Series B Preferred Stock		-	$	-		5,500	$	1,000

STOCK_OPTIONS_AND_WARRANTS_Tab

STOCK OPTIONS AND WARRANTS (Tables)	12 Months Ended
	Sep. 30, 2013
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]	'
Schedule of summary of the changes in warrants outstanding and the related prices for the shares of common Stock issued to non-employees of the company	'
									Warrants
									Outstanding				Weighted						Exercisable
									Remaining				Average			Weighted			Weighted
	Exercise				Number				Contractual				Exercise			Average			Average
	Prices				Outstanding				Life (Years)				Price			Exercisable			Exercise Price
	$	0.04				3,000,000				1.92			$	0.04			3,000,000		$	0.04
	$	0.0441				510,784				3.79			$	0.0441			510,784		$	0.0441
	$	0.0475				3,789,489				4.79			$	0.0475			3,789,489		$	0.0475
	$	0.0553				226,081				4.27			$	0.0553			226,081		$	0.0553
	$	0.06				2,000,000				0.39			$	0.06			2,000,000		$	0.06
	$	0.071				1,000,000				1.32			$	0.071			1,000,000		$	0.071
	$	0.09				6,900,000				2.92			$	0.09			6,900,000		$	0.09
	$	0.179				100,000				2.1			$	0.179			100,000		$	0.179
	$	0.214				100,000				2.6			$	0.214			-		$	-
	$	0.2431				40,106,951				4.8			$	0.2431			40,106,951		$	0.2431
	$	0.5				1,300,000				0.12			$	0.5			1,300,000		$	0.5
						59,033,305				4.1			$	0.1976			58,933,305		$	0.1963
Schedule of transactions involving warrants	'
			Number of				Weighted Average
			Shares				Price Per Share
	Balance, September 30, 2011			58,205,280			$	0.14
	Granted			1,075,000				0.071
	Exercised			(5,039,633	)			(0.045
	Cancelled or expired			(8,400,000	)			(0.161	)
	Balance at September 30, 2012			45,840,647			$	0.145
	Granted			134,249,218				0.233
	Exercised			(60,236,873	)			(0.170	)
	Cancelled or expired			(60,819,687	)			(0.265	)
	Balance,  September 30, 2013			59,033,305				0.196
Schedule of summary of the changes in options outstanding and the related prices for the shares of common Stock issued to employees of the company under the 2005 Incentive Stock Plan	'
		Options Outstanding										Options Exercisable
		Exercise		Number				Weighted Average				Weighted Average			Number			Weighted
		Prices		Outstanding				Remaining				Exercise Price			Exercisable			Average
								Contractual										Exercise Price
								Life (Years)
	$	0.05			24,000,000				1.65			$	0.05			24,000,000		$	0.05
	$	0.0585			50,000,000				4.79			$	0.0585			50,000,000		$	0.0585
	$	0.06			30,000,000				1.76			$	0.06			30,000,000		$	0.06
	$	0.065			634,825				3.18			$	0.065			634,825		$	0.065
	$	0.068			4,770,000				3.17			$	0.068			4,770,000		$	0.068
	$	0.07			2,850,000				1.67			$	0.07			1,900,000		$	0.07
	$	0.09			1,500,000				2.92			$	0.09			1,500,000		$	0.09
	$	0.11			5,400,000				4.71			$	0.11			5,400,000		$	0.11
	$	0.1799			2,099,367				4.17			$	0.1799			-		$	-
	$	0.193			100,000				4.75			$	0.193			-		$	-
	$	0.2			100,000				4.63			$	0.2			-		$	-
					121,454,192				3.23			$	0.063			118,204,825		$	0.0605
Schedule of summary of transactions involving stock options issued to employees	'
			Number of				Weighted Average					Aggregate Intrinsic
			Shares				Exercise Price Per Share					Value
	Outstanding at October 1, 2011			120,650,000			$	0.06
	Granted			6,558,825				0.067
	Exercised			(500,000	)			(0.08	)
	Cancelled or expired			(1,500,000	)			(0.08	)
	Outstanding at September 30, 2012			125,208,825			$	0.06
	Granted			2,299,367				0.181
	Exercised			(5,979,000	)			(0.042	)
	Cancelled or expired			(75,000	)			(0.060	)
	Outstanding at September 30, 2013			121,454,192			$	0.063
	Vested at September 30, 2013			118,204,825							$	0.136
	Non-vested at September 30, 2013			3,429,367							$	0.055

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
Schedule of income tax provision (benefit)	'
		2013			2012
	Federal:
	Current	$	-		$	-
	Deferred		2,955,000			1,422,000
			2,955,000			1,422,000
	State and local:
	Current		-			-
	Deferred		407,000			196,000
			407,000			196,000
	Change in valuation allowance		(3,362,000	)		(1,618,000	)
	Income tax provision (benefit)	$	-		$	-
Schedule of effective income tax rate reconciliation	'
		September 30,
		2013			2012
	Statutory federal income tax rate		(34.00	%)		(34.00	%)
	Statutory state and local income tax rate (7.1%), net of federal benefit		(4.69	%)		(4.69	%)
	Stock based compensation		3.27	%		10.74	%
	Depreciation and amortization		(0.12	%)		(0.28	%)
	Amortization of debt discount		0	%		2.92	%
	Change in valuation allowance		35.54	%		25.31	%
	Effective tax rate		0	%		0	%
Schedule of components of deferred tax assets	'
		September 30,
		2013			2012
	Deferred tax assets (liabilities):
	Stock based compensation	$	578,000		$	768,000
	Depreciation and amortization		(21,000	)		(20,000	)
	Amortization of debt discount		-			209,000
	Net operating loss carry forward		17,913,000			14,551,000
	Less: valuation allowance		(18,470,000	)		(15,508,000	)
	Net deferred tax asset	$	-		$	-

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of future minimum rental payments	'
	2014	$	450,617
	2015		449,142
	2016		299,428
	Total		1,199,187
		$

FAIR_VALUE_Tables

FAIR VALUE (Tables)	12 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Schedule of fair Value Measurements of Common Stock Warrants Using Significant Unobservable Inputs (Level 3)	'
	Fair Value Measurements of Common Stock Warrants Using Significant Unobservable Inputs (Level 3)	Year Ended September 30,
		2013			2012
	Balance at October 1,	$	—		$	—
	Issuance of Series A and B Warrants		2,461,856			—
	Adjustment resulting from change in value recognized in earnings (a)		7,508,146			—
	Reclassification to equity upon exercise		(7,326,553	)		—
	Balance at September 30,	$	2,643,449		$	—
	(a) Adjustment resulting from change in fair value is the amount of total gains or losses for the period attributable to the change in unrealized gains or losses relating to liabilities held at the reporting date. The unrealized gain or loss is recorded in change in fair value of warrant liability in the accompanying condensed consolidated statements of operations.

LIQUIDITY_AND_MANAGEMENTS_PLAN1

LIQUIDITY AND MANAGEMENT'S PLAN (Detail Textuals) (USD $)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Liquidity [Abstract]	'	'
Net loss	($17,686,472)	($7,150,712)
Net cash used in operating activities	-7,870,353	-3,960,679
Working capital	$6,091,555	'

LIQUIDITY_AND_MANAGEMENTS_PLAN2

LIQUIDITY AND MANAGEMENT'S PLAN (Detail Textuals 1) (USD $)	12 Months Ended			1 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Nov. 29, 2012	Jul. 19, 2013
			Securities Purchase Agreement	Securities Purchase Agreement	Securities Purchase Agreement
				Crede CG II, Ltd	Crede CG III, Ltd.
Stockholders' Equity Note [Line Items]	'	'	'	'	'
Sale of common stock	$1,438,146	$2,101,000	$15,000,000	$7,500,000	$7,500,000
Net proceeds from issuance of stock	'	'	14,635,000	'	'
Payment for investment fees	'	'	$365,000	'	'

LIQUIDITY_AND_MANAGEMENTS_PLAN3

LIQUIDITY AND MANAGEMENT'S PLAN (Detail Textuals 2) (Crede, Second Purchase Agreement, USD $)	Jul. 31, 2013
Crede | Second Purchase Agreement	'
Liquidity And Management Plan [Line Items]	'
Maximum price per share to issue common stock or securities convertible into common stock	$0.19
Market price of common stock	$0.17

SUMMARY_OF_ACCOUNTING_POLICIES3

SUMMARY OF ACCOUNTING POLICIES - Property, plant and equipment (Details) (USD $)	Sep. 30, 2013	Sep. 30, 2012
Property, Plant and Equipment [Line Items]	'	'
Total	$1,105,624	$462,803
Accumulated depreciation	409,629	251,958
Property and equipment, net	695,995	210,845
Computer equipment	'	'
Property, Plant and Equipment [Line Items]	'	'
Total	43,555	33,464
Lab equipment	'	'
Property, Plant and Equipment [Line Items]	'	'
Total	657,735	296,904
Furniture	'	'
Property, Plant and Equipment [Line Items]	'	'
Total	164,997	132,435
Leasehold improvements	'	'
Property, Plant and Equipment [Line Items]	'	'
Total	$239,337	'

SUMMARY_OF_ACCOUNTING_POLICIES4

SUMMARY OF ACCOUNTING POLICIES (Detail Textuals) (USD $)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Accounting Policies [Line Items]	'	'
Accumulated deficit	($186,693,611)	($169,007,139)
Deferred revenue	148,503	'
Revenue recognized for a Government contract award	100,000	'
Allowance on accounts receivable	62,415	0
Writes-off receivables	15,000	0
Depreciation method	'straight line method	'
Estimated useful lives	'3 to 5 years	'
Depreciation expenses	157,671	41,096
Impairment of intellectual property	114,730	'
Fully diluted shares outstanding (in shares)	839,583,895	692,328,470
Stock-based compensation expense	1,926,129	1,953,844
Research and development	692,480	432,669
Advertising expense	$196,762	$97,877
Patents	'	'
Accounting Policies [Line Items]	'	'
Intangible assets, estimated useful life (in years)	'5 years	'
Intellectual property	'	'
Accounting Policies [Line Items]	'	'
Intangible assets, estimated useful life (in years)	'7 years	'

SUMMARY_OF_ACCOUNTING_POLICIES5

SUMMARY OF ACCOUNTING POLICIES (Detail Textuals 1)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2012	Sep. 30, 2012
	Total Revenue	Total Revenue	Accounts Receivable	Accounts Receivable
		Customer Two	Customer Two	Customer Three
Concentration Risk [Line Items]	'	'	'	'
Percentage of total revenue from various customers	'	54.00%	54.00%	43.00%
Total revenue, benchmark description	'No customers represented greater than 10% of the Company's total revenues	'	'	'
Concentration risk, customer	'Greater than 10%	'	'	'

INTANGIBLE_ASSETS_Identifiable

INTANGIBLE ASSETS - Identifiable intangible assets acquired (Details) (USD $)	Sep. 30, 2013	Sep. 30, 2012
Intangible Assets Disclosure [Abstract]	'	'
Trade secrets and developed technologies (Weighted average life of 7 years)	'	$3,775,889
Patents (Weighted average life of 5 years)	'	34,257
Intellectual property (Weighted average life of 5 years)	584,080	'
Total identifiable intangible assets-Gross carrying value	584,080	3,810,146
Less: Accumulated amortization	-48,674	-3,810,146
Less: Impairment charges	-114,730	'
Intangible assets, net	$420,676	'

INTANGIBLE_ASSETS_Identifiable1

INTANGIBLE ASSETS - Identifiable intangible assets acquired (Details) (Parentheticals)	12 Months Ended
	Sep. 30, 2013
Trade secrets and developed technologies	'
Acquired Finite-Lived Intangible Assets [Line Items]	'
Weighted average life (in years)	'7 years
Patents	'
Acquired Finite-Lived Intangible Assets [Line Items]	'
Weighted average life (in years)	'5 years
Intellectual Property	'
Acquired Finite-Lived Intangible Assets [Line Items]	'
Weighted average life (in years)	'5 years

INTANGIBLE_ASSETS_Estimated_am

INTANGIBLE ASSETS - Estimated amortization expense of intangible assets (Details 1) (USD $)	Sep. 30, 2013	Sep. 30, 2012
Intangible Assets Disclosure [Abstract]	'	'
2014	$90,145	'
2015	90,145	'
2016	90,145	'
2017	90,145	'
2018	60,096	'
Intangible assets, net	$420,676	'

INTANGIBLE_ASSETS_Detail_Textu

INTANGIBLE ASSETS (Detail Textuals)	12 Months Ended		0 Months Ended		12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	10-May-13	10-May-13	Sep. 30, 2013	Sep. 30, 2013
	USD ($)	USD ($)	Asset Purchase Agreement	Asset Purchase Agreement	Asset Purchase Agreement	Asset Purchase Agreement
			Redweb Technologies Limited	Redweb Technologies Limited	Redweb Technologies Limited	Redweb Technologies Limited
			USD ($)	GBP (£)	Intellectual Property	Supplies
					USD ($)	USD ($)
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'	'
Amount of purchase price	'	'	$624,080	£ 400,000	$584,080	'
Supplies expense	'	'	'	'	'	40,000
Amount held in escrow	'	'	62,408	40,000	'	'
Impairment expense	114,730	'	'	'	114,730	'
Total amortization expense charged to operations	$163,404	$272,844	'	'	'	'

ACCOUNTS_PAYABLE_AND_ACCRUED_L2

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES - Summary of accounts payable and accrued liabilities (Details) (USD $)	Sep. 30, 2013	Sep. 30, 2012
Payables and Accruals [Abstract]	'	'
Accounts payable	$641,302	$473,060
Accrued consulting fees	102,500	102,500
Accrued salaries payable	220,175	16,449
Other accrued expenses	3,000	'
Total	$966,977	$592,009

PRIVATE_PLACEMENT_OF_CONVERTIB1

PRIVATE PLACEMENT OF CONVERTIBLE NOTES - 10% Secured Convertible Promissory Note dated June 4, 2010 (Detail Textuals) (Secured Convertible Note Payable dated June 4, 2010, USD $)	1 Months Ended
	Jan. 31, 2012	Jun. 04, 2010
Secured Convertible Note Payable dated June 4, 2010	'	'
Debt Instrument [Line Items]	'	'
Convertible promissory note issued to related party	'	$675,000
Interest rate on promissory note	'	10.00%
Common stock issued in settlement of convertible debentures and interest (in shares)	6,750,248	'

PRIVATE_PLACEMENT_OF_CONVERTIB2

PRIVATE PLACEMENT OF CONVERTIBLE NOTES - 10% Senior Secured Convertible Promissory Notes dated July 15, 2010 (Details Textuals 1) (USD $)	12 Months Ended		0 Months Ended	1 Months Ended	12 Months Ended
	Sep. 30, 2012	Sep. 30, 2013	Jan. 07, 2011	Jan. 31, 2012	Sep. 30, 2012	Jan. 07, 2012	Oct. 26, 2011	Jan. 06, 2011	Jul. 15, 2010
			Secured Convertible Notes Payable dated July 15, 2010	Secured Convertible Notes Payable dated July 15, 2010	Secured Convertible Notes Payable dated July 15, 2010	Secured Convertible Notes Payable dated July 15, 2010	Secured Convertible Notes Payable dated July 15, 2010	Secured Convertible Notes Payable dated July 15, 2010	Secured Convertible Notes Payable dated July 15, 2010
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'
Converted portion of convertible promissory notes issued	'	'	$1,550,000	'	'	'	'	'	$450,000
Interest rate on promissory note	'	'	'	'	'	'	'	'	10.00%
Convertible promissory note issued to related party	'	'	'	'	'	'	'	'	2,000,000
Price at maturity for conversion into common stock	'	'	$0.04	'	'	'	'	$0.04	'
Amortization of debt discount attributable to convertible debentures	541,120	'	331,332	'	26,091	'	'	'	'
Common stock issued in settlement of convertible debentures and interest (in shares)	'	'	'	11,729,821	'	'	'	'	'
Convertible notes and related accrued interest settled	'	'	'	450,000	'	'	'	'	'
Number of shares issued in settlement of convertible notes and accrued interest	'	22,924,513	'	'	'	44,778,815	1,497,826	'	'
Convertible notes and accrued interest	'	$925,000	'	'	'	$1,550,000	$1,550,000	'	'

PRIVATE_PLACEMENT_OF_CONVERTIB3

PRIVATE PLACEMENT OF CONVERTIBLE NOTES - 10% Senior Secured Convertible Promissory Notes dated November 19, 2010 (Detail Textuals 2) (USD $)	1 Months Ended	12 Months Ended
	Nov. 30, 2011	Sep. 30, 2013	Sep. 30, 2012	Nov. 19, 2010
Debt Instrument [Line Items]	'	'	'	'
Amortization of debt discount attributable to convertible debentures	'	'	$541,120	'
Secured Convertible Notes Payable dated November 19, 2010	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'
Convertible promissory note issued to related party	'	'	'	350,000
Interest rate on promissory note	'	'	'	10.00%
Intrinsic value of the embedded beneficial conversion feature amortized to interest expense	'	-76,494	'	'
Amortization of debt discount attributable to convertible debentures	'	'	$10,479	'
Common stock issued in settlement of convertible debentures and interest (in shares)	11,693,102	'	'	'

PRIVATE_PLACEMENT_OF_CONVERTIB4

PRIVATE PLACEMENT OF CONVERTIBLE NOTES - 10% Senior Secured Convertible Promissory Note dated November 30, 2010 (Detail Textuals 3) (USD $)	1 Months Ended	12 Months Ended
	Nov. 30, 2011	Sep. 30, 2013	Sep. 30, 2012	Nov. 30, 2010
Debt Instrument [Line Items]	'	'	'	'
Amortization of debt discount attributable to convertible debentures	'	'	$541,120	'
Secured Convertible Note Payable dated November 30, 2010	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'
Convertible promissory note issued to related party	'	'	'	750,000
Interest rate on promissory note	'	'	'	10.00%
Intrinsic value of the embedded beneficial conversion feature amortized to interest expense	'	-270,078	'	'
Amortization of debt discount attributable to convertible debentures	'	'	$45,136	'
Common stock issued in settlement of convertible debentures and interest (in shares)	26,716,321	'	'	'

PRIVATE_PLACEMENT_OF_CONVERTIB5

PRIVATE PLACEMENT OF CONVERTIBLE NOTES - 10% Senior Secured Convertible Promissory Note dated January 7, 2011 (Detail Textuals 4) (USD $)	1 Months Ended	12 Months Ended
	Jan. 31, 2012	Sep. 30, 2012	Jan. 07, 2011
Debt Instrument [Line Items]	'	'	'
Amortization of debt discount attributable to convertible debentures	'	$541,120	'
Secured Convertible Note Payable dated January 7, 2011	'	'	'
Debt Instrument [Line Items]	'	'	'
Convertible promissory note issued to related party	'	'	750,000
Interest rate on promissory note	'	'	10.00%
Amortization of debt discount attributable to convertible debentures	'	$65,159	'
Common stock issued in settlement of convertible debentures and interest (in shares)	14,921,324	'	'

PRIVATE_PLACEMENT_OF_CONVERTIB6

PRIVATE PLACEMENT OF CONVERTIBLE NOTES - 10% Senior Secured Convertible Promissory Notes issued on July 15, 2010, modified on January 7, 2011 (Detail Textuals 5) (USD $)	1 Months Ended		12 Months Ended
	Jan. 31, 2012	Oct. 26, 2011	Sep. 30, 2013	Sep. 30, 2012	Jan. 07, 2011
Debt Instrument [Line Items]	'	'	'	'	'
Amortization of debt discount attributable to convertible debentures	'	'	'	$541,120	'
Secured Convertible Notes Payable, dated July 15, 2010, modified January 7, 2011	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'
Convertible promissory note issued to related party	'	'	'	'	1,550,000
Interest rate on promissory note	'	'	'	'	10.00%
Intrinsic value of the embedded beneficial conversion feature amortized to interest expense	'	'	-1,499,536	'	'
Amortization of debt discount attributable to convertible debentures	'	'	'	392,923	'
Common stock issued in settlement of convertible debentures and interest (in shares)	44,778,815	1,497,826	'	'	'
Convertible notes and related accrued interest settled	$1,447,000	$50,000	'	'	'

PRIVATE_PLACEMENT_OF_CONVERTIB7

PRIVATE PLACEMENT OF CONVERTIBLE NOTES - 4% Senior Secured Convertible Promissory Note issued on July 11, 2011 (Detail Textuals 6) (Secured Convertible Note Payable, dated July 11, 2011, USD $)	0 Months Ended
	Jul. 11, 2012	Jul. 11, 2011
Secured Convertible Note Payable, dated July 11, 2011	'	'
Debt Instrument [Line Items]	'	'
Convertible promissory note issued to related party	'	$250,000
Interest rate on promissory note	'	4.00%
Common stock issued in settlement of convertible debentures and interest (in shares)	4,444,444	'
Convertible notes and related accrued interest settled	$250,000	'

WARRANT_LIABILITY_Company_issu

WARRANT LIABILITY - Company issued Series A, B and C Warrants (Details) (USD $)	1 Months Ended
	Nov. 28, 2012	Nov. 28, 2012	Nov. 28, 2012	Jul. 19, 2013	Jul. 19, 2013	Jul. 19, 2013
	Initial Purchase Agreement	Initial Purchase Agreement	Initial Purchase Agreement	Second Purchase Agreement	Second Purchase Agreement	Second Purchase Agreement
	Crede CG II, Ltd	Crede CG II, Ltd	Crede CG II, Ltd	Crede CG III, Ltd.	Crede CG III, Ltd.	Crede CG III, Ltd.
	Series A Warrants	Series B Warrants	Series C Warrants	Series A Warrants	Series B Warrants	Series C Warrants
Class of Warrant or Right [Line Items]	'	'	'	'	'	'
Warrants issued	10,752,688	29,569,862	26,881,720	10,695,187	29,411,764	26,737,967
Warrants issued (Price per unit)	$0.22	$0.22	$0.22	$0.24	$0.24	$0.24

WARRANT_LIABILITY_Detail_Textu

WARRANT LIABILITY (Detail Textuals) (Series C Warrants, Crede, USD $)	1 Months Ended	0 Months Ended
	Jan. 22, 2013	Aug. 14, 2013
	Initial Purchase Agreement	Second Purchase Agreement
Class of Warrant or Right [Line Items]	'	'
Repurchase price	$50,000	$10,000

WARRANT_LIABILITY_Detail_Textu1

WARRANT LIABILITY (Detail Textuals 1) (USD $)	0 Months Ended		1 Months Ended			12 Months Ended
	7-May-13	Nov. 07, 2012	Apr. 25, 2013	Nov. 28, 2012	Jul. 19, 2013	Sep. 30, 2013	Sep. 30, 2013
	Warrants	Warrants	Warrants	Warrants	Warrants	Series A Warrants	Series B Warrants
			Initial Purchase Agreement	Initial Purchase Agreement	Second Purchase Agreement	Second Purchase Agreement	Second Purchase Agreement
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'
Fair value of the warrants	$15,018	$13,238	$7,326,553	$1,181,324	$1,280,532	$2,643,449	$2,643,449
Method used for determining allocated fair value of the Warrants	'Black Scholes Option Pricing Model	'Black Scholes Option Pricing Model	'Binomial Lattice model	'Binomial Lattice model	'Binomial Lattice model	'Binomial Lattice model	'Binomial Lattice model
Fair value of Common Stock	'	'	$0.22	$0.20	$0.19	$0.09	$0.09
Dividend yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Expected terms	'	'	'4 years 6 months 15 days	'5 years	'5 years	'4 years 9 months 18 days	'4 years 9 months 18 days
Risk free interest rate	0.35%	0.36%	0.71%	0.64%	1.31%	1.39%	1.39%
Expected volatility	119.72%	129.56%	125.97%	146.32%	130.09%	121.71%	121.71%
Expected price at which holders exercise Warrants	'	'	$0.22	$0.22	$0.24	$0.24	$0.24

RELATED_PARTY_TRANSACTIONS_Det

RELATED PARTY TRANSACTIONS (Detail Textuals) (USD $)	12 Months Ended		1 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Jun. 21, 2012
			Mr. Bitzer
			Abarta Partners I
Related Party Transaction [Line Items]	'	'	'
Number of shares issued in settlement of convertible notes and accrued interest	22,924,513	'	'
Convertible notes and accrued interest	$925,000	'	'
Shares issued (in shares)	'	'	35,576,568
Share issued (Price per share)	'	'	$0.04
Gross proceeds from sale of common stock	$3,900,000	$2,101,000	$1,542,600

RELATED_PARTY_TRANSACTIONS_Det1

RELATED PARTY TRANSACTIONS (Detail Textuals 1) (Divinerune Inc.)	1 Months Ended
	Jan. 25, 2012
Divinerune Inc.	'
Related Party Transaction [Line Items]	'
Period of Warrants	'3 years
Warrants issued to placement agent	1,000,000
Exercise price of warrants	0.071

CAPITAL_STOCK_Summary_of_secur

CAPITAL STOCK - Summary of securities issued (Details) (USD $)	1 Months Ended						12 Months Ended		1 Months Ended
	Nov. 28, 2012	Nov. 28, 2012	Nov. 28, 2012	Jul. 19, 2013	Jul. 19, 2013	Jul. 19, 2013	Sep. 30, 2013	Sep. 30, 2012	Nov. 28, 2012	Jul. 19, 2013
	Initial Purchase Agreement	Initial Purchase Agreement	Initial Purchase Agreement	Second Purchase Agreement	Second Purchase Agreement	Second Purchase Agreement	Common Stock	Common Stock	Common Stock	Common Stock
	Series A Warrants	Series B Warrants	Series C Warrants	Series A Warrants	Series B Warrants	Series C Warrants			Initial Purchase Agreement	Second Purchase Agreement
	Crede CG II, Ltd	Crede CG II, Ltd	Crede CG II, Ltd	Crede CG III, Ltd.	Crede CG III, Ltd.	Crede CG III, Ltd.			Crede CG II, Ltd	Crede CG III, Ltd.
Stockholders' Equity Note [Line Items]	'	'	'	'	'	'	'	'	'	'
Shares issued (in shares)	'	'	'	'	'	'	21,447,875	44,963,516	10,752,688	10,695,187
Share issued (Price per share)	'	'	'	'	'	'	'	'	$0.19	$0.19
Warrants issued	10,752,688	29,569,862	26,881,720	10,695,187	29,411,764	26,737,967	'	'	'	'
Warrants issued (Price per unit)	$0.22	$0.22	$0.22	$0.24	$0.24	$0.24	'	'	'	'

CAPITAL_STOCK_Detail_Textuals

CAPITAL STOCK (Detail Textuals) (USD $)	Sep. 30, 2013	Sep. 30, 2012	Jan. 27, 2012
Stockholders' Equity Note [Abstract]	'	'	'
Common stock, shares authorized (in shares)	1,350,000,000	1,350,000,000	800,000,000
Common stock, par value (in dollars per share)	$0.00	$0.00	'
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00	'
Common stock, shares issued (in shares)	786,526,955	646,182,550	'
Common stock, shares outstanding (in shares)	786,526,955	646,182,550	'

CAPITAL_STOCK_Details_Textuals

CAPITAL STOCK (Details Textuals 1) (USD $)	12 Months Ended			1 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Nov. 29, 2012	Jul. 19, 2013
			Securities Purchase Agreement	Securities Purchase Agreement	Securities Purchase Agreement
			agreement	Crede CG II, Ltd	Crede CG III, Ltd.
Stockholders' Equity Note [Line Items]	'	'	'	'	'
Sale of common stock	$1,438,146	$2,101,000	$15,000,000	$7,500,000	$7,500,000
Number of financing agreement	'	'	2	'	'
Net proceeds from issuance of stock	'	'	14,635,000	'	'
Payment for investment fees	'	'	$365,000	'	'

CAPITAL_STOCK_Detail_Textuals_

CAPITAL STOCK (Detail Textuals 2) (USD $)	12 Months Ended
	Sep. 30, 2013
Additional Condition [Abstract]	'
Amount of annual run rate	$15,000,000
Amount of annual receivables	3,000,000
Crede CG II, Ltd	'
Beneficial Ownership Blocker [Abstract]	'
Beneficial ownership blocker, Description	'
	The Series A and Series B Preferred and the Series A, B and C Warrants each contain a 9.9% “blocker” so that in no event shall the Series A and Series B Preferred or any of the Series A, B and C Warrants be convertible or exercisable (including through the cashless exercise exchange provision) into or for Common Stock to the extent that such conversion or exercise would result in Crede having “beneficial ownership” (within the meaning of Section 13(d) of the Securities Exchange Act of 1934, as amended) of more than 9.9% of the Common Stock. Crede would, however, have the right from time to time to convert, exercise or exchange for shares of Common Stock, which over time would aggregate to greater than 9.9% beneficial ownership if all such shares of Common Stock so acquired had been held at one time by Crede.
Percentage of blocker	9.90%
Maximum threshold for beneficial ownership	9.90%
Term for participation in other equity or equity linked financing completed	'180 days
Securities Purchase Agreement With Crede CG II Ltd	'
Exercise Of Warrants For Cash [Abstract]	'
Exercise of warrants for cash, Description	'
	Crede may exercise Series A and Series B Warrants by paying in cash or on a cashless basis by exchanging such Warrants for Common Stock using the Black-Scholes value. In the event that the Common Stock trades at a price 25% or more above the exercise price of the Series A and Series B Warrants for a period of 20 consecutive days (with average daily dollar volume of Common Stock on the OTC Bulletin Board at least equal to $300,000), the Company may obligate Crede to exercise such Warrants for cash.
Number of average daily dollar volume of common stock	$300,000
Percentage of common stock trade	25.00%
Number of trading days	'20 days
Securities Purchase Agreement With Crede CG II Ltd | Crede CG II, Ltd	'
Registration Rights Agreement [Abstract]	'
Number of days of initial closing to file registration statement	'30 days

CAPITAL_STOCK_Detail_Textuals_1

CAPITAL STOCK (Detail Textuals 3) (USD $)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Agreement [Line Items]	'	'
Net proceeds from sale of Series A and Series B Preferred Stock	$10,735,000	'
Gross proceeds from sale of common stock	$3,900,000	$2,101,000
Common Stock [Member]	'	'
Agreement [Line Items]	'	'
Shares issued (in shares)	21,447,875	44,963,516

CAPITAL_STOCK_Detail_Textuals_2

CAPITAL STOCK (Detail Textuals 4) (Crede, USD $)	1 Months Ended		0 Months Ended
	Jan. 22, 2013	Jul. 31, 2013	Aug. 14, 2013	Jan. 08, 2013	Aug. 14, 2013
	Initial Purchase Agreement	Second Purchase Agreement	Second Purchase Agreement	Common Stock	Common Stock
	Series C Warrants		Series C Warrants	Series A Preferred stock	Series B Preferred stock
Stockholders' Equity Note [Line Items]	'	'	'	'	'
Maximum price per share to issue common stock or securities convertible into common stock	'	$0.19	'	'	'
Market price of common stock	'	$0.17	'	'	'
Convertible preferred stock issued upon conversion (in shares)	'	'	'	25,462,963	42,307,692
Convertible preferred stock conversion price (dollar per share)	'	'	'	$0.22	$0.13
Repurchase price	$50,000	'	$10,000	'	'

STOCK_OPTIONS_AND_WARRANTS_Cha

STOCK OPTIONS AND WARRANTS - Changes in warrants outstanding and related prices (Details) (Warrants)	12 Months Ended
	Sep. 30, 2013	7-May-13	Nov. 07, 2012	Sep. 30, 2012	Oct. 01, 2011
Class of Warrant or Right [Line Items]	'	'	'	'	'
Exercise Price	'	0.214	0.179	'	'
Number Outstanding	59,033,305	'	'	45,840,647	58,205,280
Warrants Outstanding Remaining Contractual Life (Years)	'4 years 1 month 6 days	'	'	'	'
Weighted Average Exercise Price	0.1976	'	'	'	'
Weighted Average Exercisable	58,933,305	'	'	'	'
Exercisable Weighted Average Exercise Price	0.1963	'	'	'	'
Exercise price $0.0400	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'
Exercise Price	0.04	'	'	'	'
Number Outstanding	3,000,000	'	'	'	'
Warrants Outstanding Remaining Contractual Life (Years)	'1 year 11 months 1 day	'	'	'	'
Weighted Average Exercise Price	0.04	'	'	'	'
Weighted Average Exercisable	3,000,000	'	'	'	'
Exercisable Weighted Average Exercise Price	0.04	'	'	'	'
Exercise price $0.0441	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'
Exercise Price	0.0441	'	'	'	'
Number Outstanding	510,784	'	'	'	'
Warrants Outstanding Remaining Contractual Life (Years)	'3 years 9 months 15 days	'	'	'	'
Weighted Average Exercise Price	0.0441	'	'	'	'
Weighted Average Exercisable	510,784	'	'	'	'
Exercisable Weighted Average Exercise Price	0.0441	'	'	'	'
Exercise price $0.0475	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'
Exercise Price	0.0475	'	'	'	'
Number Outstanding	3,789,489	'	'	'	'
Warrants Outstanding Remaining Contractual Life (Years)	'4 years 9 months 15 days	'	'	'	'
Weighted Average Exercise Price	0.0475	'	'	'	'
Weighted Average Exercisable	3,789,489	'	'	'	'
Exercisable Weighted Average Exercise Price	0.0475	'	'	'	'
Exercise price $0.0553	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'
Exercise Price	0.0553	'	'	'	'
Number Outstanding	226,081	'	'	'	'
Warrants Outstanding Remaining Contractual Life (Years)	'4 years 3 months 7 days	'	'	'	'
Weighted Average Exercise Price	0.0553	'	'	'	'
Weighted Average Exercisable	226,081	'	'	'	'
Exercisable Weighted Average Exercise Price	0.0553	'	'	'	'
Exercise price $0.0600	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'
Exercise Price	0.06	'	'	'	'
Number Outstanding	2,000,000	'	'	'	'
Warrants Outstanding Remaining Contractual Life (Years)	'4 months 21 days	'	'	'	'
Weighted Average Exercise Price	0.06	'	'	'	'
Weighted Average Exercisable	2,000,000	'	'	'	'
Exercisable Weighted Average Exercise Price	0.06	'	'	'	'
Exercise price $0.0710	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'
Exercise Price	0.071	'	'	'	'
Number Outstanding	1,000,000	'	'	'	'
Warrants Outstanding Remaining Contractual Life (Years)	'1 year 3 months 26 days	'	'	'	'
Weighted Average Exercise Price	0.071	'	'	'	'
Weighted Average Exercisable	1,000,000	'	'	'	'
Exercisable Weighted Average Exercise Price	0.071	'	'	'	'
Exercise price $0.0900	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'
Exercise Price	0.09	'	'	'	'
Number Outstanding	6,900,000	'	'	'	'
Warrants Outstanding Remaining Contractual Life (Years)	'2 years 11 months 1 day	'	'	'	'
Weighted Average Exercise Price	0.09	'	'	'	'
Weighted Average Exercisable	6,900,000	'	'	'	'
Exercisable Weighted Average Exercise Price	0.09	'	'	'	'
Exercise price $0.1790	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'
Exercise Price	0.179	'	'	'	'
Number Outstanding	100,000	'	'	'	'
Warrants Outstanding Remaining Contractual Life (Years)	'2 years 1 month 6 days	'	'	'	'
Weighted Average Exercise Price	0.179	'	'	'	'
Weighted Average Exercisable	100,000	'	'	'	'
Exercisable Weighted Average Exercise Price	0.179	'	'	'	'
Exercise price $0.2140	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'
Exercise Price	0.214	'	'	'	'
Number Outstanding	100,000	'	'	'	'
Warrants Outstanding Remaining Contractual Life (Years)	'2 years 7 months 6 days	'	'	'	'
Weighted Average Exercise Price	0.214	'	'	'	'
Weighted Average Exercisable	'	'	'	'	'
Exercisable Weighted Average Exercise Price	'	'	'	'	'
Exercise price $0.2431	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'
Exercise Price	0.2431	'	'	'	'
Number Outstanding	40,106,951	'	'	'	'
Warrants Outstanding Remaining Contractual Life (Years)	'4 years 9 months 18 days	'	'	'	'
Weighted Average Exercise Price	0.2431	'	'	'	'
Weighted Average Exercisable	40,106,951	'	'	'	'
Exercisable Weighted Average Exercise Price	0.2431	'	'	'	'
Exercise price $0.5000	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'
Exercise Price	0.5	'	'	'	'
Number Outstanding	1,300,000	'	'	'	'
Warrants Outstanding Remaining Contractual Life (Years)	'1 month 13 days	'	'	'	'
Weighted Average Exercise Price	0.5	'	'	'	'
Weighted Average Exercisable	1,300,000	'	'	'	'
Exercisable Weighted Average Exercise Price	0.5	'	'	'	'

STOCK_OPTIONS_AND_WARRANTS_Tra

STOCK OPTIONS AND WARRANTS - Transactions involving warrants (Details 1) (Warrants, USD $)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Warrants	'	'
Class Of Warrant Or Right, Number Of Shares [Roll Forward]	'	'
Beginning Balance, Number of Shares	45,840,647	58,205,280
Granted	134,249,218	1,075,000
Exercised	-60,236,873	-5,039,633
Cancelled or expired	-60,819,687	-8,400,000
Ending Balance, Number of Shares	59,033,305	45,840,647
Class Of Warrant Or Right, Weighted Average Price Per Share [Roll Forward]	'	'
Beginning Balance, Weighted Average Price Per Share	$0.14	$0.14
Granted	$0.23	$0.07
Exercised	($0.17)	($0.05)
Cancelled or expired	($0.27)	($0.16)
Ending Balance, Weighted Average Price Per Share	$0.20	$0.14

STOCK_OPTIONS_AND_WARRANTS_Cha1

STOCK OPTIONS AND WARRANTS - Changes in options outstanding and related prices (Details 2) (Stock Options, USD $)

0 Months Ended

1 Months Ended

0 Months Ended

12 Months Ended

12 Months Ended

Oct. 14, 2013

Oct. 17, 2013

Jul. 02, 2013

12-May-12

Sep. 30, 2013

Sep. 30, 2012

Oct. 01, 2011

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Incentive Stock Plan 2005

Incentive Stock Plan 2005

Incentive Stock Plan 2005

Incentive Stock Plan 2005

Incentive Stock Plan 2005

Incentive Stock Plan 2005

Incentive Stock Plan 2005

Incentive Stock Plan 2005

Incentive Stock Plan 2005

Incentive Stock Plan 2005

Incentive Stock Plan 2005

Incentive Stock Plan 2005

Incentive Stock Plan 2005

Incentive Stock Plan 2005

Incentive Stock Plan 2005

Incentive Stock Plan 2005

Exercise price $0.0500

Exercise price $0.0585

Exercise price $0.0600

Exercise price $0.0650

Exercise price $0.0680

Exercise price $0.0700

Exercise price $0.0900

Exercise price $0.1100

Exercise price $0.1799

Exercise price $0.1930

Exercise price $0.2000

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise Prices

$0.09

$0.09

$0.19

$0.20

$0.18

$0.07

'

$0.05

$0.06

$0.06

$0.07

$0.07

$0.07

$0.09

$0.11

$0.18

$0.19

$0.20

Number Outstanding

'

'

'

'

121,454,192

125,208,825

120,650,000

24,000,000

50,000,000

30,000,000

634,825

4,770,000

2,850,000

1,500,000

5,400,000

2,099,367

100,000

100,000

Weighted Average Remaining Contractual Life of Options Outstanding (Years)

'

'

'

'

'3 years 2 months 23 days

'

'

'1 year 7 months 24 days

'4 years 9 months 15 days

'1 year 9 months 4 days

'3 years 2 months 5 days

'3 years 2 months 1 day

'1 year 8 months 1 day

'2 years 11 months 1 day

'4 years 8 months 16 days

'4 years 2 months 1 day

'4 years 9 months

'4 years 7 months 17 days

Weighted Average Exercise Price of Options Outstanding

'

'

'

'

$0.06

$0.06

$0.06

$0.05

$0.06

$0.06

$0.07

$0.07

$0.07

$0.09

$0.11

$0.18

$0.19

$0.20

Number Exercisable

'

'

'

'

118,204,825

'

'

24,000,000

50,000,000

30,000,000

634,825

4,770,000

1,900,000

1,500,000

5,400,000

'

'

'

Weighted Average Exercise Price

'

'

'

'

$0.06

'

'

$0.05

$0.06

$0.06

$0.07

$0.07

$0.07

$0.09

$0.11

'

'

'

STOCK_OPTIONS_AND_WARRANTS_Tra1

STOCK OPTIONS AND WARRANTS - Transactions involving stock options issued to employees (Details 3) (USD $)	12 Months Ended	0 Months Ended	1 Months Ended		0 Months Ended		12 Months Ended
	Sep. 30, 2013	Oct. 14, 2013	Oct. 17, 2013	Sep. 24, 2012	Jul. 02, 2013	12-May-12	Sep. 30, 2013	Sep. 30, 2012
		Stock Options	Stock Options	Stock Options	Stock Options	Stock Options	Stock Options	Stock Options
					Incentive Stock Plan 2005	Incentive Stock Plan 2005	Incentive Stock Plan 2005	Incentive Stock Plan 2005
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'	'	'	'	'	'	'	'
Outstanding Beginning balance, Number of Shares	'	'	'	'	'	'	125,208,825	120,650,000
Granted	'	'	3,777,780	'	100,000	100,000	2,299,367	6,558,825
Exercised	-25,000	'	'	-500,000	'	'	-5,979,000	-500,000
Cancelled or expired	'	'	'	'	'	'	-75,000	-1,500,000
Outstanding Ending Balance, Number of Shares	'	'	'	'	'	'	121,454,192	125,208,825
Vested at September 30, 2013	'	'	'	'	'	'	118,204,825	'
Non-vested at September 30, 2013	'	'	'	'	'	'	3,429,367	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]	'	'	'	'	'	'	'	'
Outstanding Beginning Balance, Weighted Average Exercise Price Per Share	'	'	'	'	'	'	$0.06	$0.06
Granted	'	$0.09	$0.09	'	$0.19	$0.20	$0.18	$0.07
Exercised	($0.06)	'	'	'	'	'	($0.04)	($0.08)
Cancelled or expired	'	'	'	'	'	'	($0.06)	($0.08)
Outstanding Ending Balance, Weighted Average Exercise Price Per Share	'	'	'	'	'	'	$0.06	$0.06
Vested at September 30, 2013	'	'	'	'	'	'	$0.14	'
Non-vested at September 30, 2013	'	'	'	'	'	'	$0.06	'

STOCK_OPTIONS_AND_WARRANTS_Tra2

STOCK OPTIONS AND WARRANTS - Transactions involving warrants (Detail Textuals) (USD $)

1 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

31-May-13

Apr. 30, 2013

Mar. 31, 2013

Sep. 30, 2013

Apr. 25, 2013

7-May-13

Nov. 07, 2012

Sep. 30, 2013

Sep. 30, 2012

Oct. 01, 2011

Nov. 29, 2012

Nov. 29, 2012

Nov. 29, 2013

Apr. 25, 2013

Nov. 28, 2012

Jul. 19, 2013

Apr. 25, 2013

Apr. 25, 2013

Sep. 30, 2013

Jan. 22, 2013

Aug. 14, 2013

Oct. 31, 2011

Sep. 30, 2012

Jan. 25, 2012

Sep. 30, 2012

Crede

Warrants

Warrants

Warrants

Warrants

Warrants

Warrants

Warrants

Warrants

Warrants

Warrants

Warrants

Series A Warrants

Series B Warrants

Series B Warrants

Series C Warrants

Series C Warrants

Warrants issued on October 31, 2011

Warrants issued on October 31, 2011

Warrants issued on January 25, 2012

Warrants issued on January 25, 2012

Maximum

Minimum

Initial Purchase Agreement

Initial Purchase Agreement

Initial Purchase Agreement

Second Purchase Agreement

Crede

Crede

Second Purchase Agreement

Initial Purchase Agreement

Second Purchase Agreement

Crede

Crede

Class of Warrant or Right [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of warrants issued for services

'

'

'

'

'

100,000

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

75,000

'

1,000,000

'

Term of warrants (in years)

'

'

'

'

'

'3 Years

'3 Years

'

'

'

'

'

'One to five years

'

'

'One to five years

'

'

'

'

'

'3 Years

'

'3 Years

'

Exercise price of warrants

'

'

'

'

'

0.214

0.179

'

'

'

'

'

0.2232

'

'

0.2431

'

'

'

'

'

0.07

'

0.071

'

Method used for determining fair value of warrants

'

'

'

'

'

'Black Scholes Option Pricing Model

'Black Scholes Option Pricing Model

'

'

'

'

'

'

'Binomial Lattice model

'Binomial Lattice model

'Binomial Lattice model

'

'

'Binomial Lattice model

'

'

'

'Black Scholes Option Pricing Model

'

'Black Scholes Option Pricing Model

Fair value assumptions, dividend yield

'

'

'

'

'

0.00%

0.00%

'

'

'

'

'

'

0.00%

0.00%

0.00%

'

'

0.00%

'

'

'

0.00%

'

0.00%

Fair value assumptions, volatility rate

'

'

'

'

'

119.72%

129.56%

'

'

'

'

'

'

125.97%

146.32%

130.09%

'

'

121.71%

'

'

'

157.69%

'

147.53%

Fair value assumptions, risk free rate

'

'

'

'

'

0.35%

0.36%

'

'

'

'

'

'

0.71%

0.64%

1.31%

'

'

1.39%

'

'

'

0.41%

'

0.81%

Number of warrants exercised during period

'

'

'

'

'

'

'

60,236,873

5,039,633

'

'

'

'

'

'

'

10,752,688

29,569,892

'

'

'

'

'

'

5,039,633

Fair value of the warrants

'

'

'

'

'

$15,018

$13,238

'

'

'

'

'

'

$7,326,553

$1,181,324

$1,280,532

'

'

$2,643,449

'

'

'

$1,363

'

$56,875

Expected terms

'

'

'

'

'

'

'

'

'

'

'

'

'

'4 years 6 months 15 days

'5 years

'5 years

'

'

'4 years 9 months 18 days

'

'

'

'

'

'

Number of warrants outstanding

'

'

'

'

'

'

'

59,033,305

45,840,647

58,205,280

'

'

67,204,300

'

'

'

'

'

'

'

'

'

'

'

'

Number of years for exercisable of warrants

'

'

'

'

'

'

'

'

'

'

'5 years

'1 year

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued

'

'

'

'

31,257,045

'

'

'

'

'

'

'

'

'

'

66,844,918

'

'

'

'

'

'

'

'

'

Common stock issued in connection with the exercise of warrants

'

'

1,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price of warrants

'

'

$0.10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net proceeds from exercise of warrants

'

'

150,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued in connection with the cashless exercise

2,418,971

11,285,376

'

4,639,483

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of stock in connection with the cashless exercise of options (in shares)

2,975,956

15,438,337

'

5,954,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price

$0.04

$0.06

'

$0.05

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments for repurchase of warrants

'

'

'

60,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of warrants repurchased

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

26,881,720

26,737,967

'

'

'

'

Repurchase price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$50,000

$10,000

'

'

'

'

Number of common stock issued in settlement of warrants exercised

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,012,160

STOCK_OPTIONS_AND_WARRANTS_Emp

STOCK OPTIONS AND WARRANTS - Employee Stock Options (Detail Textuals 1) (Stock Options, Incentive Stock Plan 2005, USD $)	1 Months Ended	12 Months Ended
	Jan. 27, 2012	Sep. 30, 2013
Stock Options | Incentive Stock Plan 2005	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Issuance of common stock as stock awards and stock options	350,000,000	'
Issuance of additional common Stock as stock awards and stock options	50,000,000	'
Cumulative number of shares issued	'	$10,175,000
Options to purchase Shares under the 2005 Incentive Stock Plan	'	125,208,825

STOCK_OPTIONS_AND_WARRANTS_Emp1

STOCK OPTIONS AND WARRANTS - Employee Stock Options (Detail Textuals 2) (USD $)

1 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

31-May-13

Apr. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Oct. 14, 2013

Oct. 17, 2013

15-May-13

Sep. 24, 2012

Sep. 30, 2013

Sep. 30, 2012

Jul. 02, 2013

12-May-12

Sep. 30, 2013

Sep. 30, 2012

Oct. 01, 2011

Dec. 06, 2011

Nov. 30, 2011

Mar. 16, 2012

Feb. 08, 2012

Aug. 20, 2013

Nov. 30, 2012

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Non-employee Stock Option

Incentive Stock Plan 2005

Incentive Stock Plan 2005

Incentive Stock Plan 2005

Incentive Stock Plan 2005

Incentive Stock Plan 2005

Director

Director

Employee

Employee

Former Chief Financial Officer

Director

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of stock options granted to purchase the Company's common stock (in shares)

'

'

'

'

'

3,777,780

'

'

'

'

100,000

100,000

2,299,367

6,558,825

'

634,825

5,724,000

100,000

100,000

'

2,099,367

Term of options granted

'

'

'

'

'

'

'

'

'

'

'5 years

'5 years

'

'

'

'5 years

'5 years

'5 years

'5 years

'

'5 years

Vesting period of options issued

'

'

'

'

'

'5 years

'

'

'

'

'

'4 years

'

'

'

'

'

'

'

'

'1 year

Method used to determine fair value of options

'

'

'

'

'

'

'

'

'

'

'Black-Scholes Option Pricing Model

'Black Scholes Option Pricing Model

'

'

'

'Black-Scholes Option Pricing Model

'Black-Scholes Option Pricing Model

'Black-Scholes Option Pricing Model

'Black-Scholes Option Pricing Model

'

'Black Scholes Option Pricing Model

Percentage of vesting in each year

'

'

'

'

'

'

'

'

'

'

25.00%

25.00%

'

'

'

'

'

25.00%

25.00%

'

'

Fair value of options, dividend yield

'

'

'

'

'

'

'

'

'

'

0.00%

0.00%

'

'

'

0.00%

0.00%

0.00%

0.00%

'

0.00%

Fair value of options, volatility rate

'

'

'

'

'

'

'

'

'

'

114.00%

117.57%

'

'

'

156.29%

156.65%

149.81%

152.56%

'

146.33%

Fair value of options, risk free rate

'

'

'

'

'

'

'

'

'

'

1.01%

0.60%

'

'

'

0.94%

0.96%

1.13%

0.82%

'

0.82%

Fair value of options, exercise price

'

'

'

'

$0.09

$0.09

'

'

'

'

$0.19

$0.20

$0.18

$0.07

'

$0.07

$0.07

$0.06

$0.07

'

$0.18

Number of options expired

'

'

'

'

'

'

'

1,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of options set to expire to June 16, 2018

'

'

'

'

'

'

5,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Period for exercise of vested options

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'1 year

'

Number of options vested during period

'

'

'

'

'

'

'

'

'

'

'

'

118,204,825

'

'

'

'

'

'

20,500,000

'

Common stock issued in connection with the cashless exercise

2,418,971

11,285,376

4,639,483

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of common stock issued in settlement of options exercised

2,975,956

15,438,337

5,954,000

'

'

'

'

349,114

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price

$0.04

$0.06

$0.05

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of common stock issued in connection with exercise of options

'

'

25,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of options exercises (in shares)

'

'

25,000

'

'

'

'

500,000

'

'

'

'

5,979,000

500,000

'

'

'

'

'

'

'

Stock option exercise price (in dollars per share)

'

'

$0.06

'

'

'

'

'

'

'

'

'

$0.04

$0.08

'

'

'

'

'

'

'

Stock-based compensation expense

'

'

$1,926,129

$1,953,844

'

'

'

'

$1,926,129

$1,953,844

'

'

'

'

'

'

'

'

'

'

'

Unrecorded compensation cost related to non-vested awards

'

'

'

'

'

'

'

'

107,462

107,462

'

'

'

'

'

'

'

'

'

'

'

Incremental stock compensation expense connection with modification

'

'

'

'

'

'

'

'

$408,605

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price per share (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

$0.06

$0.06

$0.06

'

'

'

'

'

'

INCOME_TAXES_Provision_Benefit

INCOME TAXES - Provision (Benefit) (Details) (USD $)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Federal:	'	'
Current	'	'
Deferred	2,955,000	1,422,000
Federal income tax expense benefit, total	2,955,000	1,422,000
State and local:	'	'
Current	'	'
Deferred	407,000	196,000
State and local income tax expense benefit, total	407,000	196,000
Change in valuation allowance	-3,362,000	-1,618,000
Income tax provision (benefit)	'	'

INCOME_TAXES_Provision_for_inc

INCOME TAXES - Provision for income taxes differ from amount of income tax determined (Details 1)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Income Tax Disclosure [Abstract]	'	'
Statutory federal income tax rate	-34.00%	-34.00%
Statutory state and local income tax rate (7.1%), net of federal benefit	-4.69%	-4.69%
Stock based compensation	3.27%	10.74%
Depreciation and amortization	-0.12%	-0.28%
Amortization of debt discount	0.00%	2.92%
Change in valuation allowance	35.54%	25.31%
Effective tax rate	0.00%	0.00%

INCOME_TAXES_Provision_for_inc1

INCOME TAXES - Provision for income taxes differ from amount of income tax determined (Details 1) (Parentheticals)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Income Tax Disclosure [Abstract]	'	'
Statutory rate & local income tax rate including portion of federal benefit	7.10%	7.10%

INCOME_TAXES_Components_of_def

INCOME TAXES - Components of deferred tax assets (Details 2) (USD $)	Sep. 30, 2013	Sep. 30, 2012
Deferred tax assets (liabilities):	'	'
Stock based compensation	$578,000	$768,000
Depreciation and amortization	-21,000	-20,000
Amortization of debt discount	'	209,000
Net operating loss carry forward	17,913,000	14,551,000
Less: valuation allowance	-18,470,000	-15,508,000
Net deferred tax asset	'	'

INCOME_TAXES_Detail_Textuals

INCOME TAXES (Detail Textuals) (USD $)	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
Operating loss carryforwards	$46,300,000

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES - Future minimum rental payments (Details) (USD $)	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
2014	$450,617
2015	449,142
2016	299,428
Total	$1,199,187

COMMITMENTS_AND_CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Detail Textuals) (USD $)	0 Months Ended	12 Months Ended
	Jun. 14, 2013	Sep. 30, 2013	Sep. 30, 2012
	sqft
Commitments and Contingencies Disclosure [Abstract]	'	'	'
Area of property under operating lease	30,000	'	'
Extended operating lease for two additional period	'3 years	'	'
Base rent during initial lease term per annum	$449,142	'	'
Total lease rental expenses	'	$352,867	$244,192

COMMITMENTS_AND_CONTINGENCIES_3

COMMITMENTS AND CONTINGENCIES (Detail Textuals 1) (Employment agreement, USD $)	Jul. 11, 2011	Jul. 11, 2011	Jul. 11, 2011	Sep. 30, 2013	Jul. 11, 2011	Jul. 11, 2011	Jul. 11, 2011
	James A. Hayward	James A. Hayward	James A. Hayward	Kurt H. Jensen	Kurt H. Jensen	Kurt H. Jensen	Kurt H. Jensen
		Vesting on grant date	Vesting on each of next two anniversaries of grant date			Vesting on grant date	Vesting on each of next two anniversaries of grant date
Commitments and Contingencies [Line Items]	'	'	'	'	'	'	'
Share price	($0.06)	'	'	'	($0.06)	'	'
Percentage of vesting in each year	'	25.00%	37.50%	'	'	25.00%	37.50%
Conditional benchmark revenue to determine vesting percentage	'	$1,000,000	'	'	'	$1,000,000	'
Description of vesting terms	'	'If Company's revenues for any fiscal quarter increase by more than $1 million over the prior fiscal quarter, then the vesting date for the next 37.5% tranche will be accelerated.	'	'	'	'If Company's revenues for any fiscal quarter increase by more than $1 million over the prior fiscal quarter, then the vesting date for the next 37.5% tranche will be accelerated.	'
Number of shares granted	'	40,000,000	'	'	'	10,000,000	'
Additional options granted	'	15,000,000	'	'	'	'	'
Period to exercise the shares	'	'	'	'	'	'1 year	'
Number of shares vested but unexercised	'	'	'	'	'	20,500,000	'
Accrued amount related to resignation agreement	'	'	'	$79,000	'	'	'

COMMITMENTS_AND_CONTINGENCIES_4

COMMITMENTS AND CONTINGENCIES (Detail Textuals 2)	12 Months Ended
	Sep. 30, 2013
	Claim
Commitments and Contingencies Disclosure [Abstract]	'
Number of claims alleged in the amended complaint	17
Number of claims asserted against the company	5
Number of claims dismissed against asserted claims	4

FAIR_VALUE_Activity_of_Level_3

FAIR VALUE - Activity of Level 3 inputs measured on a recurring basis (Details) (Common Stock Warrants, USD $)	12 Months Ended
	Sep. 30, 2013		Sep. 30, 2012		Sep. 30, 2011
Common Stock Warrants	'		'		'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]	'		'		'
Balance at October 1,	'		'		'
Issuance of Series A and B Warrants	2,461,856		'		'
Adjustment resulting from change in value recognized in earnings	7,508,146	[1]	'	[1]	'
Reclassification to equity upon exercise	-7,326,553		'		'
Balance at September 30,	$2,643,449		'		'
[1]	Adjustment resulting from change in fair value is the amount of total gains or losses for the period attributable to the change in unrealized gains or losses relating to liabilities held at the reporting date. The unrealized gain or loss is recorded in change in fair value of warrant liability in the accompanying condensed consolidated statements of operations.

SUBSEQUENT_EVENTS_Detail_Textu

SUBSEQUENT EVENTS (Detail Textuals) (USD $)	Apr. 25, 2013	Sep. 30, 2013	Sep. 30, 2012	Apr. 25, 2013	Apr. 25, 2013	Oct. 14, 2013	Dec. 16, 2013	Oct. 14, 2013	Dec. 16, 2013	Dec. 16, 2013
	Crede	Warrants	Warrants	Series A Warrants	Series B Warrants	Subsequent Event	Subsequent Event	Subsequent Event	Subsequent Event	Subsequent Event
				Crede	Crede		Crede	Karol Gray	Series A Warrants	Series B Warrants
									Crede	Crede
Subsequent Event [Line Items]	'	'	'	'	'	'	'	'	'	'
Officers compensation	'	'	'	'	'	'	'	$336,000	'	'
Period of grant	'	'	'	'	'	'5 years	'	'5 years	'	'
Number of shares granted	'	'	'	'	'	2,000,000	'	2,000,000	'	'
Number of shares to be purchased on exercise of warrants	31,257,045	'	'	'	'	'	18,823,073	'	'	'
Number of warrants exercised during period	'	60,236,873	5,039,633	10,752,688	29,569,892	'	'	'	10,695,187	7,000,000

SUBSEQUENT_EVENTS_Detail_Textu1

SUBSEQUENT EVENTS (Detail Textuals 1) (USD $)

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

Oct. 14, 2013

Oct. 17, 2013

Mar. 16, 2012

Feb. 08, 2012

Oct. 14, 2013

Dec. 10, 2013

Nov. 28, 2013

Oct. 14, 2013

Oct. 17, 2013

Nov. 28, 2013

Oct. 14, 2013

Oct. 14, 2013

Oct. 17, 2013

Dec. 02, 2013

Oct. 17, 2013

Dec. 02, 2013

Oct. 17, 2013

Oct. 17, 2013

Stock Options

Stock Options

Stock Options

Stock Options

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Employee

Employee

Employee

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Vesting on each anniversary for next four years

Vesting on each anniversary for next four years

Immediate vesting

Chairman CEO And President

Chairman CEO And President

Chairman CEO And President

Chief Technology Officer

Chief Technology Officer

Chief Technology Officer

Vesting on each anniversary for next four years

Vesting on each anniversary for next four years

Vesting on each anniversary for next four years

Subsequent Event [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of options granted

'

3,777,780

100,000

100,000

2,000,000

2,126,000

250,000

7,928,000

3,777,780

'

'

'

50,000,000

'

'

2,000,000

3,000,000

'

Exercise price per share of options granted

$0.09

$0.09

$0.06

$0.07

'

$0.14

$0.12

$0.09

$0.09

'

'

'

$0.10

'

'

$0.12

$0.10

'

Term of options granted

'

'

'5 years

'5 years

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

Vesting period of options issued

'

'5 years

'

'

'5 years

'

'5 years

'5 years

'5 years

'

'

'

'5 years

'

'

'5 years

'5 years

'

Percentage of vesting in each year

'

'

25.00%

25.00%

'

'

'

'

'

25.00%

25.00%

'

'

25.00%

25.00%

'

'

25.00%

Vested at September 30, 2013

'

'

'

'

'

'

'

'

'

'

5,928,000

2,000,000

'

'

'

'

'

'